

09/623828

## Certificate of Mailing

Date of Deposit September 8, 2000Label Number: EL507497291US

I hereby certify under 37 CFR 1.10 that this correspondence is being deposited with the United States Postal Service as "Express Mail Post Office to Addressee" with sufficient postage on the date indicated above and is addressed to BOX PCT, Commissioner for Patents, Washington, D.C. 20231.

Elvis De La Cruz

Printed name of person mailing correspondence

Signature of person mailing correspondence

Substitute Form PTO 1390 U.S. Department of Commerce Patent and Trademark Office		Attorney's Docket Number: 50146/004002
TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371		U.S. Application Number: [**US SERIAL NUMBER**]
INTERNATIONAL APPLICATION NUMBER	INTERNATIONAL FILING DATE	PRIORITY DATE CLAIMED
PCT/FR99/00547	March 11, 1999	March 11, 1998
TITLE OF INVENTION:	QUALITATIVE DIFFERENTIAL SCREENING	
APPLICANTS FOR DO/EO/US:	Fabien Schweighoffer, Laurent Bracco, Bruno Tocque	
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:		
1.	<input checked="" type="checkbox"/> This is a FIRST submission of items concerning a filing under 35 U.S.C. 371.	
2.	<input type="checkbox"/> This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371.	
3.	<input checked="" type="checkbox"/> This is an express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1).	
4.	<input checked="" type="checkbox"/> A proper Demand for International Preliminary Examination was made by the 19 <sup>th</sup> month from the earliest claimed priority date.	
5.	A copy of the International Application as filed (35 U.S.C. 371(c)(2)). <input checked="" type="checkbox"/> a. is transmitted herewith (required only if not transmitted by the International Bureau). <input type="checkbox"/> b. has been transmitted by the International Bureau. <input type="checkbox"/> c. is not required, as the application was filed with the United States Receiving Office (RO/US).	
6.	<input checked="" type="checkbox"/> A translation of the International Application into English (35 U.S.C. 371(c)(2)).	
7.	Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3)). <input type="checkbox"/> a. are transmitted herewith (required only if not transmitted by the International Bureau). <input checked="" type="checkbox"/> b. have been transmitted by the International Bureau. <input type="checkbox"/> c. have not been made; however, the time limit for making such amendments has NOT expired. <input type="checkbox"/> d. have not been made and will not be made.	
8.	<input type="checkbox"/> A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).	
9.	<input checked="" type="checkbox"/> An unsigned oath or declaration of the inventors (35 U.S.C. 371(c)(4)).	
10.	<input checked="" type="checkbox"/> A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).	
11.	<input type="checkbox"/> An Information Disclosure Statement under 37 CFR 1.97 and 1.98.	
12.	<input checked="" type="checkbox"/> Two Small Entity Declarations which are copies from prior application 09/046,920 and such small entity status is still proper and desired.	
13.	<input type="checkbox"/> An assignment for recording. A separate cover sheet in compliance with 37 C.F.R. 3.28 and 3.31 is included.	

14.	<input type="checkbox"/> A FIRST preliminary amendment. <input type="checkbox"/> A SECOND or SUBSEQUENT preliminary amendment.		
15.	<input type="checkbox"/> A substitute specification.		
16.	<input type="checkbox"/> A change of power of attorney and/or address letter.		
17.	<input type="checkbox"/> Other items or information:		
18.	<input checked="" type="checkbox"/> The following fees are submitted:  BASIC NATIONAL FEE (37 CFR 1.492(A)(1)-(5)):  Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.455(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO \$ 970.00  International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO \$ 840.00  International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO \$ 690.00  International preliminary examination fee (37 CFR 1.482) paid to USPTO but all claims did not satisfy provisions of PCT Article 33(1) - (4) \$ 870.00  International preliminary examination fee paid to USPTO (37 CFR 1.482) and all claims satisfied provisions of PCT Article 33(1)-(4) \$ 96.00		\$840.00
ENTER APPROPRIATE BASIC FEE AMOUNT =		\$840.00	
Surcharge of \$130 for furnishing the oath or declaration later than <input type="checkbox"/> 20 OR <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(e)).		\$	
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE
Total claims	[**] - 20 =		x \$18.00 \$
Independent claims	[**] - 3 =		x \$78.00 \$
Multiple dependent claims (if applicable)		+ \$260.00	\$
TOTAL OF ABOVE CALCULATIONS =		\$840.00	
Reduction of 1/2 for filing by small entity, if applicable. Verified Small Entity Statement must also be filed with this request (Note 37 CFR 1.9, 1.27, 1.28).		\$420.00	
SUBTOTAL =		\$ 420.00	
Processing fee of \$130.00 for furnishing the English translation later than <input type="checkbox"/> 20 OR <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(f)).		+	\$
TOTAL NATIONAL FEE =		\$ 420.00	
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property.		+	\$
TOTAL FEES ENCLOSED =		\$ 420.00	
		Amount to be refunded	\$
		charged	\$

#3

ATTORNEY DOCKET NO. 50146/004002

Applicant or Patentee : Fabien Schweighoffer et al.  
 Serial or Patent No. : 09/623,828  
 Filed or Issued : September 8, 2000  
 Title : DIFFERENTIAL QUALITATIVE SCREENING

**VERIFIED STATEMENT (DECLARATION) CLAIMING SMALL ENTITY STATUS**  
**(37 CFR 1.9(f) and 1.27(c)) - SMALL BUSINESS CONCERN**

I hereby declare that I am

- ☐ the owner of the small business concern identified below:  
☒ an official of the small business concern empowered to act on behalf of the concern identified below:

Name of Small Business Concern: ExonHit Therapeutics S.A.

Address of Small Business Concern: 63-65 boulevard Masséna - 75013 PARIS - FRANCE

I hereby declare that the above identified small business concern qualifies as a small business concern as defined in 13 CFR 121.12, and reproduced in 37 CFR 1.9(d), for purposes of paying reduced fees to the United States Patent and Trademark Office, in that the number of employees of the concern, including those of its affiliates, does not exceed 500 persons. For purposes of this statement, (1) the number of employees of the business concern is the average over the previous fiscal year of the concern of the persons employed on a full-time, part-time or temporary basis during each of the pay periods of the fiscal year, and (2) concerns are affiliates of each other when either, directly or indirectly, one concern controls or has the power to control the other, or a third party or parties controls or has the power to control both.

I hereby declare that rights under contract or law have been conveyed to and remain with the small business concern identified above with regard to the invention, entitled DIFFERENTIAL QUALITATIVE SCREENING by inventors Fabien Schweighoffer, Laurent Bracco, and Bruno Tocque described in

- ☐ the specification filed herewith.  
☒ application serial no. 09/623,828, filed September 8, 2000  
☐ patent no. ["PATENT NUMBER"], issued ["ISSUE DATE"].

If the rights held by the above identified small business concern are not exclusive, each individual, concern or organization having rights to the invention is listed below and no rights to the invention are held by any person, other than the inventor, who would not qualify as an independent inventor under 37 CFR 1.9(c) if that person made the invention, or by any concern which would not qualify as a small business concern under 37 CFR 1.9(d), or a nonprofit organization under 37 CFR 1.9(e). NOTE: Separate verified statements are required from each named person, concern or organization having rights to the invention averring to their status as small entities. (37 CFR 1.27)

Assignee Name:

Assignee Address:

☐ INDIVIDUAL ☐ SMALL BUSINESS CONCERN ☐ NONPROFIT ORGANIZATION

I acknowledge the duty to file, in this application or patent, notification of any change in status resulting in loss of entitlement to small entity status prior to paying, or at the time of paying, the earliest of the issue fee or any maintenance fee due after the date on which status as a small entity is no longer appropriate. (37 CFR 1.28(b))

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application, any patent issuing thereon, or any patent on which this verified statement is directed.

Name: Bruno Tocque

Title: CEO

Address: 58 boulevard Saint Denis, F-92400 Courbevoie, France

Signature: 

Date: October 26, 2000

Applicant or Patentee : Fabien Schweighoffer et al.  
 Serial or Patent No. : 09/046,920  
 Filed or Issued : March 24, 1998  
 Title : DIFFERENTIAL QUALITATIVE SCREENING

VERIFIED STATEMENT (DECLARATION) CLAIMING SMALL ENTITY STATUS  
 (37 CFR 1.9(f) and 1.27(c)) - SMALL BUSINESS CONCERN

I hereby declare that I am

☒

the owner of the small business concern identified below;  
 or an official of the small business concern empowered to act on behalf of the concern identified below:

Name of Small Business Concern: Bioscreen Therapeutics S.A.

Address of Small Business Concern: 58 boulevard Saint Denis, F-92400 Courbevoie, FRANCE

I hereby declare that the above identified small business concern qualifies as a small business concern as defined in 13 CFR 121.12, and reproduced in 37 CFR 1.9(d), for purposes of paying reduced fees to the United States Patent and Trademark Office, in that the number of employees of the concern, including those of its affiliates, does not exceed 500 persons. For purposes of this statement, (1) the number of employees of the business concern is the average over the previous fiscal year of the concern of the persons employed on a full-time, part-time or temporary basis during each of the pay periods of the fiscal year, and (2) concerns are affiliates of each other when either, directly or indirectly, one concern controls or has the power to control the other, or a third party or parties controls or has the power to control both.

I hereby declare that rights under contract or law have been conveyed to and remain with the small business concern identified above with regard to the invention, entitled DIFFERENTIAL QUALITATIVE SCREENING by inventors Fabien Schweighoffer, Laurent Bracco, and Bruno Tocque described in

- ☐ the specification filed herewith.  
☒ application serial no. 09/046,920, filed March 24, 1998.  
☐ patent no. ["PATENT NUMBER"], issued ["ISSUE DATE"].

If the rights held by the above identified small business concern are not exclusive, each individual, concern or organization having rights to the invention is listed below and no rights to the invention are held by any person, other than the inventor, who would not qualify as an independent inventor under 37 CFR 1.9(c) if that person made the invention, or by any concern which would not qualify as a small business concern under 37 CFR 1.9(d), or a nonprofit organization under 37 CFR 1.9(e). NOTE: Separate verified statements are required from each named person, concern or organization having rights to the invention averting to their status as small entities. (37 CFR 1.27)

Assignee Name:

Assignee Address:

☐ INDIVIDUAL ☒ SMALL BUSINESS CONCERN ☐ NONPROFIT ORGANIZATION

I acknowledge the duty to file, in this application or patent, notification of any change in status resulting in loss of entitlement to small entity status prior to paying, or at the time of paying, the earliest of the issue fee or any maintenance fee due after the date on which status as a small entity is no longer appropriate. (37 CFR 1.28(b))

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application, any patent issuing thereon, or any patent on which this verified statement is directed.

Name:

Tocque

Title:

C.E.O

Address: 58 boulevard Saint Denis, F-92400 Courbevoie, France

Signature:

*[Handwritten Signature]*

Date:

May 29, 1998

Applicant or Patentee : Fabien Schweighoffer et al.  
 Serial or Patent No. : 09/046,920  
 Filed or Issued : March 24, 1998  
 Title : DIFFERENTIAL QUALITATIVE SCREENING

VERIFIED STATEMENT (DECLARATION) CLAIMING SMALL ENTITY STATUS  
 (37 CFR 1.9(f) and 1.27(c)) - SMALL BUSINESS CONCERN

I hereby declare that I am

- ☐ the owner of the small business concern identified below:  
☐ an official of the small business concern empowered to act on behalf of the concern identified below:

Name of Small Business Concern: ExonHit Therapeutics S.A.

Address of Small Business Concern: 63-65 boulevard Masséna - 75013 PARIS - FRANCE

I hereby declare that the above identified small business concern qualifies as a small business concern as defined in 13 CFR 121.12, and reproduced in 37 CFR 1.9(d), for purposes of paying reduced fees to the United States Patent and Trademark Office, in that the number of employees of the concern, including those of its affiliates, does not exceed 500 persons. For purposes of this statement, (1) the number of employees of the business concern is the average over the previous fiscal year of the concern of the persons employed on a full-time, part-time or temporary basis during each of the pay periods of the fiscal year, and (2) concerns are affiliates of each other when either, directly or indirectly, one concern controls or has the power to control the other, or a third party or parties controls or has the power to control both.

I hereby declare that rights under contract or law have been conveyed to and remain with the small business concern identified above with regard to the invention, entitled DIFFERENTIAL QUALITATIVE SCREENING by inventors Fabien Schweighoffer, Laurent Bracco, and Bruno Tocque described in

- ☐ the specification filed herewith.  
☒ application serial no. 09/046,920, filed March 24, 1998.  
☐ patent no. ["PATENT NUMBER"], issued ["ISSUE DATE"].

If the rights held by the above identified small business concern are not exclusive, each individual, concern or organization having rights to the invention is listed below and no rights to the invention are held by any person, other than the inventor, who would not qualify as an independent inventor under 37 CFR 1.9(c) if that person made the invention, or by any concern which would not qualify as a small business concern under 37 CFR 1.9(d), or a nonprofit organization under 37 CFR 1.9(e). \*NOTE: Separate verified statements are required from each named person, concern or organization having rights to the invention averring to their status as small entities. (37 CFR 1.27)

Assignee Name:

Assignee Address:

☐ INDIVIDUAL ☐ SMALL BUSINESS CONCERN ☐ NONPROFIT ORGANIZATION

I acknowledge the duty to file, in this application or patent, notification of any change in status resulting in loss of entitlement to small entity status prior to paying, or at the time of paying, the earliest of the issue fee or any maintenance fee due after the date on which status as a small entity is no longer appropriate. (37 CFR 1.28(b))

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application, any patent issuing thereon, or any patent on which this verified statement is directed.

Name:

*Tocque Bruno*

Title:

*CEO*

Address: 58 boulevard Saint Denis, F-92400 Courbevoie, France

Signature:

*[Signature]*

Date:

*5 June 1998*

DIFFERENTIAL SCREENING

The present invention relates to the fields of biotechnology medicine, biology and biochemistry. Applications thereof are aimed at human health, animal and plant care. More particularly, the invention makes it possible to identify nucleic acid sequences whereby both novel screening methods for identifying molecules of therapeutic interest and novel gene therapy tools can be developed, and it further provides information on the toxicity and potency of molecules, as well as pharmacogenomic data.

The present invention primarily describes a set of original methods for identifying nucleic acid sequences which rely on demonstrating qualitative differences between RNAs derived from two distinct states being compared, in particular those derived from a diseased organ or tissue and healthy equivalents thereof. More specifically, these methods are intended to specifically clone alternative exons and introns which are differentially spliced with respect to a pathological condition and a healthy state or with respect to two physiological conditions one wishes to compare. These qualitative differences in RNAs can also be due to genome alterations such as insertions or deletions in the regions to be transcribed to RNA. This set of methods is identified by the acronym DATAS : Differential Analysis of Transcripts with Alternative Splicing.

The characterization of gene expression alterations which underly or are linked to a given disorder raises substantial hope regarding the discovery of novel therapeutic targets and of original diagnostic tools. However, the identification of a genomic or complementary DNA sequence, whether through positional cloning or quantitative differential screening techniques, yields little, if any, information on the function, and even less on the functional domains, involved in the regulation defects related to the disease under study. The present invention describes a set of original methods aimed at identifying differences in RNA splicing occurring between two distinct pathophysiological conditions. Identifying such differences provides information on qualitative but not on quantitative differences as has been the case for techniques described so far. The techniques disclosed in the present invention are hence all encompassed under the term of "qualitative differential screening", or DATAS. The methods of the invention may be used to identify novel targets or therapeutic products, to devise genetic research and/or diagnostic tools, to construct nucleic acid libraries, and to develop methods for determining the toxicological

profile or potency of a compound for example.

A first object of the invention is based more particularly on a method for identifying and/or cloning nucleic acid regions which correspond to qualitative genetic differences occurring between two biological samples, comprising  
 5 hybridizing a population of double stranded cDNAs or RNAs derived from a first biological sample, with a population of cDNAs derived from a second biological sample (Figure 1A).

As indicated hereinabove, the qualitative genetic differences may be due to alterations of RNA splicing or to deletions and/or insertions in the regions of the  
 10 genome which are transcribed to RNA.

In a first embodiment, the hybridization is carried out between RNAs derived from a first biological sample and cDNAs (single stranded or double stranded) derived from a second biological sample.

In another embodiment, the hybridization is carried out between double  
 15 stranded cDNAs derived from a first biological sample, and cDNAs (double stranded or, preferably, single stranded) derived from a second biological sample.

A more specific object of the invention is to provide a method for identifying differentially spliced nucleic acid regions occurring between two physiological conditions, comprising hybridizing a population of RNAs or double stranded cDNAs  
 20 derived from a test condition with a population of cDNAs originating from a reference condition and identifying nucleic acids which correspond to differential splicing events.

Another object of the invention is to provide a method for cloning differentially spliced nucleic acids occurring between two physiological conditions, comprising  
 25 hybridizing a population of RNAs or double stranded cDNAs derived from the test condition with a population of cDNAs originating from the reference condition and cloning nucleic acids which correspond to differential splicing events.

In a particular embodiment, the method of nucleic acid identification and/or cloning according to the invention comprises running two hybridizations in parallel  
 30 consisting of :

(a) hybridizing RNAs derived from the first sample (test condition) with cDNAs derived from the second sample (reference condition);

(b) hybridizing RNAs derived from the second sample (reference condition) with cDNAs derived from the first sample (test condition) ; and

(c) identifying and/or cloning, from the hybrids formed in steps (a) and (b), those nucleic acids corresponding to qualitative genetic differences.

The present invention is equally directed to the preparation of nucleic acid libraries, to the nucleic acids and libraries thus prepared, as well as to uses of such materials in all fields of biology/biotechnology, as illustrated hereinafter.

In this respect, the invention is equally directed to a method for preparing profiled nucleic acid compositions or libraries, representative of qualitative differences occurring between two biological samples, comprising hybridizing RNAs derived from a first biological sample with cDNAs originating from a second biological sample.

The invention further concerns a method for profiling a cDNA composition, comprising hybridizing this composition with RNAs, or vice versa.

As indicated hereinabove, the present invention relates in particular to methods for identifying and cloning nucleic acids representative of a physiological state. In addition, the nucleic acids identified and/or cloned represent the qualitative characteristics of a physiological state in that these nucleic acids are generally involved to a great extent in the physiological state being observed. Thus, the qualitative methods of the invention afford direct exploration of genetic elements or protein products thereof, playing a functional role in the development of a pathophysiological state.

The methods of the invention are partly based on an original step consisting of cross hybridization between RNAs and cDNAs belonging to distinct physiological states. This or these cross hybridization procedures advantageously allow one to demonstrate, in the hybrids formed, unpaired regions, i.e. regions present in RNAs in a given physiological condition and not in RNAs from another physiological condition. Such regions essentially correspond to alternative forms of splicing typical of a physiological state, but may also be a reflection of genetic alterations such as insertions or deletions, and thus form genetic elements particularly useful in the fields of therapeutics and diagnostics as set forth below. The invention therefore consists notably in keeping the complexes formed after cross hybridization(s), so as to deduce therefrom the regions corresponding to qualitative differences. This methodology can be distinguished from quantitative subtraction techniques known to those skilled in the art (Sargent and Dawid (1983), Science, 222: 135-139 ; Davis et al. (1984), PNAS, 81: 2194-2198 ; Duguid and Dinauer (1990), Nucl. Acid Res., 18:



2789-2792 ; Diatchenko et al. (1996), PNAS, 93: 6025-6030), which discard the hybrids formed after hybridization(s) so as to conserve only the non-hybridized nucleic acids.

The invention therefore first deals with a method for identifying nucleic acids of interest comprising hybridizing the RNAs of a test sample with the cDNAs of a reference sample. This hybridization procedure makes it possible to identify, in the complexes formed, qualitative genetic differences between the conditions under study, and thus to identify and/or clone for example the splicings which are characteristic of the test condition.

According to a first variant of the invention, the method therefore allows one to generate a nucleic acid population characteristic of splicing events that occur in the physiological test condition as compared to the reference condition (Figure 1A, 1B). As indicated hereinafter, this population can be used for the cloning and characterization of nucleic acids, their use in diagnostics, screening, therapeutics and antibody production or synthesis of whole proteins or protein fragments. This population can also be used to generate libraries that may be used in different fields of application as shown hereinafter and to generate labeled probes (Figure 1D).

According to another variant of the invention, the method comprises a first hybridization as described hereinbefore and a second hybridization, conducted in parallel, between RNAs derived from the reference condition and cDNAs derived from the test condition. This variant is particularly advantageous since it allows one to generate two nucleic acid populations, one representing the qualitative characteristics of the test condition with respect to the reference condition, and the other representing the qualitative characteristics of the reference condition in relation to the test condition (Figure 1C). These two populations can also be utilized as nucleic acid sources, or as libraries which serve as genetic fingerprints of a particular physiological condition, as will be more fully described in the following (Figure 1D).

The present invention may be applied to all types of biological samples. In particular, the biological sample can be any cell, organ, tissue, sample, biopsy material, etc. containing nucleic acids. In the case of an organ, tissue or biopsy material, the samples can be cultured so as to facilitate access to the constituent cells. The samples may be derived from mammals (especially human beings), plants, bacteria and lower eukaryotes (yeasts, fungal cells, etc.). Relevant materials

- are exemplified in particular by a tumor biopsy, neurodegenerative plaque or cerebral zone biopsy displaying neurodegenerative signs, a skin sample, a blood sample obtained by collecting blood, a colorectal biopsy, biopsy material derived from bronchoalveolar lavage, etc. Examples of cells include notably muscle cells,
- 5 hepatic cells, fibroblasts, nerve cells, epidermal and dermal cells, blood cells such as B and T lymphocytes, mast cells, monocytes, granulocytes and macrophages.

As indicated hereinabove, the qualitative differential screening according to the present invention allows the identification of nucleic acids characteristic of a given physiological condition (condition B) in relation to a reference physiological

10 condition (condition A), that are to be cloned or used for other applications. By way of illustration, the physiological conditions A and B being investigated may be chosen among the following :

CONDITION A	CONDITION B
Healthy subject-derived sample	Pathological sample
Healthy subject-derived sample	Apoptotic sample
Healthy subject-derived sample	Sample obtained after viral infection
X-sensitive sample	X-resistant sample
Untreated sample	Treated sample (for example by a toxic compound)
Undifferentiated sample	Sample that has undergone cellular or tissue differentiation

#### 15 RNA populations

The present invention can be carried out by using total RNAs or messenger RNAs. These RNAs can be prepared by any conventional molecular biology methods, familiar to those skilled in the art. Such methods generally comprise cell, tissue or sample lysis and RNA recovery by means of extraction procedures. This

20 can be done in particular by treatment with chaotropic agents such as guanidium thiocyanate (which disrupts the cells without affecting RNA) followed by RNA extraction with solvents (phenol, chloroform for instance). Such methods are well

known in the art (see Maniatis et al., Chomczynski et al., (1987), Anal. Biochem., 162: 156). These methods may be readily implemented by using commercially available kits such as for example the US73750 kit (Amersham) or the Rneasy kit (Quiagen) for total RNAs. It is not necessary that the RNA be in a fully pure state, and in particular, traces of genomic DNA or other cellular components (protein, etc.) remaining in the preparations will not interfere, in as much as they do not significantly affect RNA stability and as the modes of preparation of the different samples under comparison are the same. Optionally, it is further possible to use messenger RNA instead of total RNA preparations. These may be isolated, either directly from the biological sample or from total RNAs, by means of polyT sequences, according to standard methods. In this respect, the preparation of messenger RNAs can be carried out using commercially available kits such as for example the US72700 kit (Amersham) or the kit involving the use of oligo-(dT) beads (Dynal). An advantageous method of RNA preparation consists in extracting cytosolic RNAs and then cytosolic polyA<sup>+</sup> RNAs. Kits allowing the selective preparation of cytosolic RNAs that are not contaminated by premessenger RNAs bearing unspliced exons and introns are commercially available. This is the case in particular for the Rneasy kit marketed by Qiagen (example of catalog number : 74103). RNAs can also be obtained directly from libraries or other samples prepared beforehand and/or available from collections, stored under suitable conditions.

Generally, the RNA preparations used advantageously comprise at least 0.1 µg of RNA, preferably at least 0.5 µg of RNA. Quantities can vary depending on the particular cells and methods being used, while keeping the practice of the invention unchanged. In order to obtain sufficient quantities of RNA (preferably at least 0.1 µg), it is generally recommended to use a biological sample including at least 10<sup>5</sup> cells. In this respect, a typical biopsy specimen generally comprises from 10<sup>5</sup> to 10<sup>8</sup> cells, and a cell culture on a typical petri dish (6 to 10 cm in diameter) contains about 10<sup>6</sup> cells, so that sufficient quantities of RNA can be readily obtained.

The RNA preparations may be used extemporaneously or stored, preferably in a cold place, as a solution or in the frozen state, for later use.

#### cDNA populations

The cDNA used within the scope of the present invention may be obtained

by reverse transcription according to conventional molecular biology techniques. Reference is made in particular to Maniatis et al. Reverse transcription is generally carried out using an enzyme, reverse transcriptase, and a primer.

In this respect, many reverse transcriptases have been described in the literature and are commercially available (1483188 kit, Boehringer). Examples of the most commonly employed reverse transcriptases include those derived from avian virus AMV (Avian Myeloblastosis Virus) and from murine leukemia virus MMLV (Moloney Murine Leukemia Virus). It is also worth mentioning certain thermostable DNA polymerases having reverse transcriptase activity such as those isolated from *Thermus flavus* and *Thermus thermophilus* HB-8 (commercially available; Promega catalog numbers M1941 and M2101). According to an advantageous variant, the present invention is practiced using AMV reverse transcriptase since this enzyme, active at 42°C (in contrast to that of MMLV which is active at 37°C), destabilizes certain RNA secondary structures that might stop elongation, and therefore allows reverse transcription of RNA of greater length, and provides cDNA preparations in high yields that are much more faithful copies of RNA.

According to a further advantageous variant of the invention, a reverse transcriptase devoid of RNaseH activity is employed. The use of this type of enzyme has several advantages, particularly that of increasing the yield of cDNA synthesis and avoiding any degradation of RNAs, which will then be engaged in heteroduplex formation with the newly synthesized cDNAs, thereby optionally making it possible to omit the phenol extraction of the latter. Reverse transcriptases devoid of RNaseH activity may be prepared from any reverse transcriptase by deletion(s) and/or mutagenesis. In addition, such enzymes are also commercially available (for example Life Technologies, catalog number 18053-017).

The operating conditions that apply to reverse transcriptases (concentration and temperature) are well known to those skilled in the art. In particular, 10 to 30 units of enzyme are generally used in a single reaction, in the presence of an optimal  $Mg^{2+}$  concentration of 10 mM.

The primer(s) used for reverse transcription may be of various types. It might be, in particular, a random oligonucleotide comprising preferably from 4 to 10 nucleotides, advantageously a hexanucleotide. Use of this type of random primer has been described in the literature and allows random initiation of reverse transcription at different sites within the RNA molecules. This technique is

especially employed for reverse transcribing total RNA (i.e. comprising mRNA, tRNA and rRNA in particular). Where it is desired to carry out reverse transcription of mRNA only, it is advantageous to use an oligo-dT oligonucleotide as primer, which allows initiation of reverse transcription starting from polyA tails specific to messenger RNAs. The oligo-dT oligonucleotide may comprise from 4 to 20-mers, advantageously about 15-mers. Use of such a primer represents a preferred embodiment of the invention. In addition, it might be advantageous to use a labeled primer for reverse transcription. As a matter of fact, this allows recognition and/or selection and/or subsequent sorting of RNA from cDNA. This may also allow one to isolate RNA/DNA heteroduplexes the formation of which represents a crucial step in the practice of the invention. Labeling of the primer may be done by any ligand-receptor based system, i.e. providing affinity mediated separation of molecules bearing the primer. It may consist for instance of biotin labeling, which can be captured on any support (bead, column, plates, etc.) previously coated with streptavidin. Any other labeling system allowing separation without affecting the properties of the primer may be likewise utilized.

In typical operating conditions, this reverse transcription generates single stranded complementary DNA (cDNA). This represents a first advantageous embodiment of the present invention.

In a second variant of practicing the invention, reverse transcription is accomplished such that double stranded cDNAs are prepared. This result is achieved by generating, following transcription of the first cDNA strand, the second strand using conventional molecular biology techniques involving enzymes capable of modifying DNA such as phage T4 DNA ligase, DNA polymerase I and phage T4 DNA polymerase.

The cDNA preparations may be used extemporaneously or stored, preferably in a cold place, as a solution or in the frozen state, for later use.

### Hybridizations

As set forth hereinabove, the methods according to the invention are partly based on an original cross hybridization step between RNAs and cDNAs derived from biological samples in distinct physiological conditions or from different origins. In a preferred embodiment, hybridization according to the invention is advantageously performed in the liquid phase. Furthermore, it may be carried out in

any appropriate device, such as for example tubes (Eppendorff tubes, for instance), plates or any other suitable support that is commonly used in molecular biology. Hybridization is advantageously carried out in volumes ranging from 10 to 1000  $\mu$ l, for example from 10 to 500  $\mu$ l. It should be understood that the particular device as well as the volumes used can be easily adapted by those skilled in the art. The amounts of nucleic acids used for hybridization are equally well known in the art. In general, it is sufficient to use a few micrograms of nucleic acids, for example in the range of 0.1 to 100  $\mu$ g.

An important factor to be considered when performing hybridization is the respective quantities of nucleic acids used. Thus, it is possible to use nucleic acids in a cDNA/RNA ratio ranging from 50 to 0.02 approximately, preferably from 40 to 0.1. In a more particularly advantageous manner, the cDNA/RNA ratio is preferably close to or greater than 1. Indeed, in such experiments, RNA forms the tester compound and cDNA forms the driver. Accordingly, in order to improve the specificity of the method, it is preferred to choose operating conditions where the driver is in excess relative to the tester. In fact, in such conditions, the cooperativity effect between nucleic acids occurs and mismatches are strongly disfavored. As a result, the only mismatches that are observed are generally due to the presence of regions in the tester RNA which are absent from the driver cDNA and which can therefore be considered as specific. In order to enhance the specificity of the method, hybridization is therefore advantageously performed using a cDNA/RNA ratio comprised between about 1 and about 10. It is understood that this ratio can be adapted by those skilled in the art depending on the operating conditions (nucleic acid quantities available, physiological conditions, required results, etc.). The other hybridization parameters (time, temperature, ionic strength) are also adaptable by those skilled in the art. Generally speaking, after denaturation of the tester and driver (by heating for instance), hybridization is accomplished for about 2 to 24 hours, at a temperature of approximately 37°C (and by optionally performing temperature shifts as set forth below), and under standard ionic strength conditions (ranging from 0.1 M to 5 M NaCl for instance). It is known that ionic strength is one of the factors that defines hybridization stringency, notably in the case of hybridization on a solid support.

According to a specific embodiment of the invention, hybridization is carried out in phenol emulsion, for instance according to the PERT technique (Phenol

Emulsion DNA Reassociation Technique) described by Kohne D.E. et al. (Biochemistry, (1977), 16 (24): 5329-5341). Advantageously, use is made within the scope of the present invention of phenol emulsion hybridization under temperature cycling (temperature shifts from about 37°C to about 60/65°C) instead of stirring, according to the technique of Miller and Riblet (NAR, (1995), 23: 2339). Any other liquid phase hybridization technique, notably in emulsion phase, may be used within the scope of the present invention. Thus, in another particularly advantageous embodiment, hybridization is carried out in a solution containing 80 % formamide, at a temperature of 40°C for instance.

Hybridization may also be carried out with one of the partners fixed to a support. Advantageously, the cDNA is immobilized. This may be done by taking advantage of cDNA labeling (see hereinabove), especially by using biotinylated primers. Biotin moieties are contacted with magnetic beads coated with streptavidin molecules. cDNAs can then be held in contact with the filter or the microtiter dish well by applying a magnetic field. Under appropriate ionic strength conditions, RNAs are subsequently contacted with cDNAs. Unpaired RNAs are eliminated by washing. Hybridized RNAs as well as cDNAs are recovered upon removal of the magnetic field.

Where the cDNA is double stranded, the hybridization conditions used are essentially similar to those described hereinabove, and adaptable by those skilled in the art. In this case, hybridization is preferably performed in the presence of formamide and the complexes are exposed to a range of temperatures varying for instance from 60 to 40°C, preferably from 56°C to 44°C, so as to promote the formation of R-loop complexes. In addition, it is desirable to add, following hybridization, a stabilizing agent to stabilize the triplex structures formed, once formamide is removed from the medium, such as glyoxal for example (Kaback et al., (1979), Nuc. Acid Res., 6: 2499-2517).

These cross hybridizations according to the invention thus generate compositions comprising cDNA/RNA heteroduplex or heterotriplex structures, representing the qualitative properties of each physiological condition being tested. As already noted, in each of the present compositions, nucleic acids essentially corresponding to differential alternative splicing or to other genetic alterations, specific to each physiological condition, can be identified and/or cloned.

The invention therefore advantageously relates to a method for identifying

and/or cloning nucleic acid regions representative of genetic differences occurring between two physiological conditions, comprising hybridizing RNAs derived from a biological sample in a first physiological condition with single stranded cDNAs derived from a biological sample in a second physiological condition, and identifying and/or cloning, from the hybrids thus formed, unpaired RNA regions.

This first variant is more specifically based upon the formation of heteroduplex structures between RNAs and single stranded cDNAs (see Figures 2-4). This variant is advantageously implemented using messenger RNAs or cDNAs produced by reverse transcription of essentially messenger mRNAs, i.e. in the presence of an oligo-dT primer.

In a particular embodiment, the method for identifying and/or cloning nucleic acids according to the invention comprises :

(a) hybridizing RNAs derived from the test condition with single stranded cDNAs derived from the reference condition;

(b) hybridizing RNAs derived from the reference condition with single stranded cDNAs derived from the test condition ; and

(c) identifying and/or cloning, from the hybrids formed in steps (a) and (b), unpaired RNA regions.

In a particular alternative mode of execution, the method of the invention comprises the following steps :

(a) obtaining RNAs from a biological sample in a physiological condition A (rA);

(b) obtaining RNAs from an identical biological sample in a physiological condition B (rB);

(c) preparing cDNAs from a portion of rA RNAs provided in step (a) (cA cDNAs) and from a portion of rB RNAs provided in step B (cB cDNAs) by means of polyT primers,

(d) hybridizing in liquid phase a portion of rA RNAs with a portion of cB DNAs (to generate rA/cB heteroduplexes)

(e) hybridizing in liquid phase a portion of rB RNAs with a portion of cA DNAs (to generate rB/cA heteroduplexes),

(f) identifying and/or cloning unpaired RNA regions within the rA/cB and rB/cA heteroduplexes obtained in steps (d) and (e).

According to an alternative mode of practicing the invention, the method of



the invention comprises hybridizing RNAs derived from the test condition with double stranded cDNAs derived from the reference condition, and identifying and/or cloning the resulting double stranded DNA regions. This second variant is more specifically based upon the formation of heterotriplex structures between RNAs and double stranded cDNAs, derived from R-loop type structures (see Figure 5). This variant is equally preferentially practiced by using messenger RNAs or cDNAs produced by reverse transcription of essentially messenger RNA, i.e. in the presence of a polyT primer. In this variant again, a particular embodiment comprises running two hybridizations in parallel, whereby two nucleic acid populations according to the invention are generated. In this variant, the desired regions, specific of alternative splicing events, are not the unpaired RNA regions, but instead double stranded DNA which was not displaced by a homologous RNA sequence (see Figure 5).

In another variant of the invention, the method to detect qualitative genetic differences (eg., alternative splicing events) occurring between two samples, comprises hybridizing double stranded cDNAs derived from a first biological sample with cDNAs (double stranded or, preferably single stranded) derived from a second biological sample (Figure 6).

Unlike the variants described hereinabove, this variant does not make use of DNA/RNA heteroduplex or heterotriplex structures, but instead of DNA/DNA homoduplexes. This variant is advantageous in that it reveals not only alternative introns and exons but also, and within a same nucleic acid library, specific junctions formed by deletion of an exon or an intron. Furthermore, the sequences in such a library give information about the flanking sequences of alternative introns and exons.

For both samples (i.e. pathophysiological conditions) under study, cytosolic polyA<sup>+</sup> RNAs are extracted by techniques known in the art and described previously. These RNAs are converted to cDNA through the action of a reverse transcriptase with or without intrinsic RNase H activity, as described hereinabove.

One of these single stranded cDNAs is then converted to double stranded cDNA by priming with random hexamers and according to techniques known to those skilled in the art. For one of the conditions under study one therefore has a single stranded cDNA (called a "driver") and for the other condition, a double-stranded cDNA (called a "tester"). These cDNAs are denatured by heating and then mixed such that the

driver is in excess relative to the tester. This excess is chosen between 1 and 50-fold, advantageously 10-fold. In a given experiment, conducted starting with two pathophysiological conditions, the choice of the condition which generates the driver is arbitrary and must not affect the nature of the data collected. As a matter of fact,

5 as in the case of the approaches described hereinabove, the strategy for identifying qualitative differences occurring between two mRNA populations is based on cloning these differences present in common messengers: the strategy is based on cloning sequences present within duplexes instead of single strands corresponding to unique sequences or sequences in excess in one of the conditions under study. The

10 mixture of cDNAs is precipitated, then taken up in a solution containing formamide (for example, 80 %). Hybridization is carried out for 16 hours to 48 hours, advantageously for 24 hours. The hybridization products are precipitated, then subjected to the action of a restriction endonuclease having a 4-base recognition site for double stranded DNA. Such a restriction enzyme will therefore cleave the

15 double stranded cDNA formed during the hybridization on average every 256 bases. This enzyme is advantageously chosen so as to generate cohesive ends. Such enzymes are exemplified by restriction enzymes such as Sau3AI, HpaII, TaqI and MseI. The double stranded fragments digested by these enzymes are therefore accessible to a cloning strategy making use of the cleaved restriction sites. Such

20 fragments are of two types : fully hybridized fragments, the two strands of which are fully complementary, and partially hybridized fragments, i.e. comprising a single stranded loop flanked by double stranded regions (Figure 6A). These latter fragments, which are in the minority, contain the information of interest. In order to separate them from fully hybridized fragments, which are in the majority since they

25 are derived from most of the cDNA length, separation methods on a gel or on any other suitable matrix are used. These methods take advantage of the slower migration, during electrophoresis or gel filtration in particular, of DNA fragments which contain a single stranded DNA loop. In this manner the minority fragments which contain the desired information can be preparatively separated from the majority of

30 fragments corresponding to identical DNA regions in both populations. This variant, which makes it possible to isolate, from a same population, positive and negative fingerprints linked to qualitative differences, can also be practiced with RNA/DNA heteroduplex structures. In this respect, an example of slower migration of a RNA/DNA heteroduplex in which a portion of the RNA is not paired, as compared to

a homologous heteroduplex in which all the sequences are paired, is illustrated in the grb2/grb33 model described in the examples (in particular see Figure 8, lanes 2 and 3).

#### Identification and/or cloning

Starting from nucleic acid populations generated by hybridization, the regions characterizing qualitative differences (eg., differential alternative splicing events), may be identified by any technique known to those skilled in the art.

. Identification and/or cloning starting with RNA/DNA heteroduplexes

Hence, in case of an RNA/DNA heteroduplex (first variant of this method), these regions essentially appear as unpaired RNA regions (RNA loops), as shown in Figure 3. These regions may thus be identified and cloned by separating the heteroduplexes and single stranded nucleic acids (DNA, RNA) (unreacted nucleic acids in excess), selectively digesting the double stranded RNA (portions engaged in heteroduplex structures) and finally separating the resulting single stranded RNA from the single stranded DNA.

In this respect, according to a first approach illustrated in Figure 3, the unpaired RNA regions are identified by treatment of heteroduplexes by means of an enzyme capable of selectively digesting the RNA domains engaged in RNA/DNA heteroduplexes. Enzymes having such activity are known from the prior art and are commercially available. It can be mentioned RNases H, such as in particular, those derived from *E. coli* by recombinant techniques and commercially available (Promega catalog number M4281 ; Life Technologies catalog number 18021). This first treatment thus generates a mixture comprising unpaired single stranded RNA regions and single stranded cDNA. The RNAs may be separated from cDNAs by any technique known in the art, and notably on the basis of labeling of those primers used to prepare cDNA (see above). These RNAs can be used as a source of material for identifying targets, gene products of interest or for any other application. These RNAs can be equally converted into cDNA, and then cloned into vectors, as described hereinafter.

In this regard, cloning RNAs may be done in different ways. One way is to insert at each RNA end oligonucleotides acting as templates for a reverse transcription reaction in the presence of compatible primers. Primers may be appended according to techniques well known to those skilled in the art by means of

an enzyme, such as for example RNA ligase derived from phage T4 and which catalyzes intermolecular phosphodiester bond formation between a 5' phosphate group of a donor molecule and a 3' hydroxyl group of an acceptor molecule. Such an RNA ligase is commercially available (for example Life Technologies - GIBCO BRL catalog number 18003). The cDNAs thus obtained may then be amplified by conventional techniques (PCR for example) using the appropriate primers, as illustrated in Figure 3. This technique is especially adapted to cloning short RNA molecules (less than 1000 bases).

Another approach for cloning and/or identifying specific RNA regions involves for example a reverse transcription reaction, performed upon the digests of an enzyme acting specifically on double stranded RNA, such as RNase H, using random primers, which will randomly initiate transcription along RNAs. cDNAs thus obtained are then amplified according to conventional molecular biology techniques, for example by PCR using primers formed by appending oligonucleotides to cDNA ends by means of T4 phage DNA ligase (commercially available ; for example from Life Technologies - GIBCO BRL catalog number 18003). This second technique is illustrated in Figure 4 and in the examples. This technique is especially adapted to long RNAs, and provides a sufficient part of the sequence data to subsequently reconstruct the entire initial sequence.

A further approach for cloning and/or identifying specific RNA regions is equally based on a reverse transcription reaction using random primers (Figure 4). However, according to this variant, the primers used are at least in part semi-random primers, i.e. oligonucleotides comprising :

- a random (degenerated) region,
- a minimal priming region having a defined degree of constraint, and
- a stabilizing region.

Preferably, these are oligonucleotides comprising, in the 5' → 3' direction :

- a stabilizing region comprising 8 to 24 defined nucleotides, preferably 10 to 18 nucleotides. This stabilizing region may itself correspond to the sequence of an oligonucleotide used to reamplify fragments derived from initial amplifications performed by means of the semi-random primers of the invention. In addition, the stabilizing region may comprise the sequence of one or more sites, preferably non-palindromic, corresponding to restriction enzymes. This makes it possible for example to simplify the cloning of the fragments thus amplified. A particular

example of a stabilizing region is given by the sequence GAG AAG CGT TAT (residues 1 to 12 of SEQ ID NO:1);

- a random region having 3 to 8 nucleotides, more particularly 5 to 7 nucleotides, and

- a minimal priming region defined such that the oligonucleotide hybridizes on average at least about every 60 base pairs, preferably about every 250 base pairs. More preferentially, the priming region comprises 2 to 4 defined nucleotides, preferably 3 or 4, such as for example AGGX, where X is one of the four bases A, C, G or T. The presence of such a priming region gives the oligonucleotide the capacity to hybridize on average about every 256 base pairs.

In an especially preferential manner, the oligonucleotides have the formula :

GAGAAGCGTTATNNNNNNNAGGX (SEQ ID NO: 1) where the fixed bases are ordered so as to minimize background due to self-pairing in PCR experiments, where N indicates that the four bases may be present in a random fashion at the indicated position, and where X is one of the four bases A, C, G or T. Such oligonucleotides equally constitute an object of the present invention.

In this respect, so as to increase the priming events on the RNAs to be cloned, reactions may be carried out in parallel with oligonucleotides such as :

GAGAAGCGTTATNNNNNNNAGGT (oligonucleotides A)

GAGAAGCGTTATNNNNNNNAGGA (oligonucleotides B)

GAGAAGCGTTATNNNNNNNAGGC (oligonucleotides C)

GAGAAGCGTTATNNNNNNNAGGG (oligonucleotides D),

each oligonucleotide population (A, B, C, D) being able to be used alone or in combination with another.

After the reverse transcription reaction, the cDNAs are amplified by PCR using oligonucleotides A or B or C or D.

As indicated hereinabove, depending on the complexity and the specificity of the desired oligonucleotide population, the number of degenerated positions may range from 3 to 8, preferably from 5 to 7. Below 3 hybridizations are limited and above 8 the oligonucleotide population is too complex to ensure good amplification of specific bands.

Furthermore, the length of the fixed 3' end (constrained priming region) of these oligonucleotides may also be modified : while the primers described above, with 4 fixed bases, allow amplification of 256 base pair fragments on average,

primers with 3 fixed bases allow amplification of shorter fragments (64 base pairs on average). In a first preferred embodiment of the invention, one uses oligonucleotides in which the priming region comprises 4 fixed bases. In another preferred embodiment of the invention, one uses oligonucleotides having a priming region of 3 fixed bases. In fact, as exons have an average size of 137 bases, they are advantageously amplified with such oligonucleotides. In this respect, refer also to oligonucleotides with sequence SEQ ID NO: 2, 3 and 4, for example.

Finally, in general, the identification and/or cloning step of RNA is based on different methods of PCR and cloning, so as to generate as much information as possible.

. Identification and/or cloning starting with heterotriplexes.

In the case of heterotriplex structures (another variant of the method), the qualitatively different regions (insertions, deletions, differential splicing) appear essentially in the form of double stranded DNA regions, as shown in Figure 5. Such regions may thus be identified and cloned by treating them in the presence of appropriate enzymes such as an enzyme capable of digesting RNA, and next by an enzyme capable of digesting single stranded DNA. The nucleic acids are thus directly obtained in the form of double stranded DNA and can be cloned into any suitable vector, such as the vector pMos-Blue (Amersham, RPN 5110), for example. This methodology should be distinguished from previously described approaches using RNAs or oligonucleotides of predetermined sequences, modified so as to have nuclease activity (Landgraf et al., (1994), *Biochemistry*, 33: 10607-10615).

. Identification and/or cloning starting with DNA/DNA homoduplexes (Figure 6).

The fragments isolated on the basis of their atypical structures are then ligated, at each of their ends, to adaptors, or linkers, having cleaved restriction sites at one of their ends. This step may be carried out according to the techniques known to those skilled in the art, for example by ligation with phage T4 DNA ligase. The restriction sites thus introduced are chosen to be compatible with the sites of the cDNA fragments. The linkers introduced are double stranded cDNA sequences, of known sequence, making it possible to generate the primers for enzymatic amplifications (PCR). Since the next step consists in amplifying the two strands which each bear the qualitative differences to be identified, it is necessary to use linkers with phosphorylated 5' ends. Thus after heat denaturation of double

stranded cDNA appended with linkers, each of these cDNA ends is covalently linked to a specific priming sequence. Following PCR by means of appropriate specific primers, two categories of double stranded cDNA are obtained : fragments which contain sequences specific of qualitative differences which distinguish the two pathophysiological conditions, and fragments which comprise the negative fingerprint of these splicing events. Cloning these fragments generates an alternative splicing library in which, for each splicing event, positive and negative fingerprints are present. This library therefore gives access not only to alternative exons and introns but also to the specific junctions formed by excision of these spliced sequences. In a same library, this differential genetic information may be derived from two pathophysiological conditions indiscriminately. Furthermore, so as to check the differential nature of the identified splicing events and so as to determine the condition in which they are specifically elicited, the clones in the library may be hybridized with probes derived from each of the total mRNA populations.

The cDNA fragments derived from the qualitative differences so identified have two principal uses :

- cloning into suitable vectors so as to construct libraries representative of the qualitative differences occurring between the two pathophysiological conditions under study,
- use as probes to screen a DNA library allowing identification of differential splicing events.

The vectors used in the invention can be in particular plasmids, cosmids, phages, YAC, HAC, etc. These nucleic acids may thus be stored as such, or introduced into microorganisms compatible with the cloning vector being used, for replication and/or stored in the form of cultures.

The time interval required for carrying out the methods herein described for each sample is generally less than two months, in particular less than 6 weeks. Furthermore, these different methods may be automated so that the total length of time is reduced and treatment of a large number of samples is simplified.

In this regard, another object of the invention concerns nucleic acids that have been identified and/or cloned by the methods of the invention. As already noted, these nucleic acids may be RNAs or cDNAs. More generally, the invention concerns a nucleic acid composition, essentially comprising nucleic acids

corresponding to alternative splicings which are distinctive of two physiological conditions. More particularly, these nucleic acids correspond to alternative splicings identified in a biological test sample and not present in the same biological sample under a reference condition. The invention is equally concerned with the use of the nucleic acids thus cloned as therapeutic or diagnostic products, or as screening tools to identify active molecules, as set forth hereinafter.

The different methods disclosed hereinabove thus all lead to the cloning of cDNA sequences representative of differentially spliced genetic information between two pathophysiological conditions. The whole set of clones derived from one of these methods makes it thus possible to construct a library representative of qualitative differences occurring between two conditions of interest.

#### Generation of qualitative libraries

In this respect, the invention is further directed to a method for preparing nucleic acid libraries representative of a given physiological state of a biological sample. This method advantageously comprises cloning nucleic acids representative of qualitative markers of genetic expression (for example alternative splicings) of said physiological state but not present in a reference state, to generate libraries specific to qualitative differences occurring between the two states being investigated.

These libraries are constituted by cDNA inserted in plasmid or phage vectors. Such libraries can be deposited on nitrocellulose filters or any other support known to those skilled in the art, such as chips or biochips.

One of the features as well as one of the original characteristics of qualitative differential screening is that this technique leads not to one but advantageously to two differential libraries which represent the whole set of qualitative differences occurring between two given conditions : a library pair (see Figure 1D).

Thus, the invention preferentially concerns any nucleic acid composition or library that can be obtained by hybridizing RNAs derived from a first biological sample with cDNAs derived from a second biological sample. More preferentially, the libraries or compositions of the invention comprise nucleic acids representative of qualitative differences in expression between two biological samples, and are generated by a method comprising (i) at least one hybridization step between RNAs derived from a first biological sample and cDNAs derived from a second biological



sample, (ii) selecting those nucleic acids representative of qualitative differences in expression and, optionally, (iii) cloning said nucleic acids.

Furthermore, once such libraries are constructed, it is possible to proceed with a step of clone selection in order to improve the specificity of the resulting libraries. Indeed, it may be that certain mismatches observed are not due solely to qualitative differences (eg., to differential alternative splicings) but might result from reverse transcription defects for example. Although such events are not generally significant, it is preferable to prevent them or reduce their incidence prior to nucleic acid cloning. To accomplish this, the library clones may be hybridized with the cDNA populations occurring in both physiological conditions being investigated (cf. step © hereinabove). The clones which hybridize in a non-differential manner with both populations would be considered as nonspecific and optionally discarded or treated as second priority (in fact, the appearance of a new isoform in the test sample does not always indicate that the initial isoform present in the reference sample has disappeared from this test sample). Clones hybridizing with only one of either populations or hybridizing preferentially with one of the populations are considered specific and could be selected in priority to constitute enriched or refined libraries.

A refining step may be equally performed by hybridizing and checking the identify of clones by means of probes derived from a statistically relevant number of pathological samples.

The present application is therefore equally directed to any nucleic acid library comprising nucleic acids specific to alternative splicings typical of a physiological condition. These libraries advantageously comprise cDNAs, generally double stranded, corresponding to RNA regions specific of alternative splicing. Such libraries may be comprised of nucleic acids, generally incorporated within a cloning vector, or of cell cultures containing said nucleic acids.

The choice of initial RNAs partly determines the characteristics of the resulting libraries :

- the RNAs of both conditions A and B are mRNAs or total mature RNAs isolated according to techniques known to those skilled in the art. The libraries are thus so-called restricted qualitative differential screening libraries, since they are restricted to qualitative differences that characterize the mature RNAs of both pathophysiological conditions.

- the RNAs of one of either conditions are mRNAs or mature total RNAs whereas the RNAs of the other condition are premessenger RNAs, not processed by splicing, isolated according to techniques known to those skilled in the art, from cell nuclei. In this situation the resulting libraries are so-called complex differential screening libraries, as being not restricted to differences between mature RNAs but rather comprising the whole set of spliced transcripts in a given condition which are absent from the other, including all introns.

- finally, the RNAs could arise from a single pathophysiological condition and in this case the differential screening involves mature RNAs and premessenger RNAs of the same sample. In such a case, the resulting libraries are autologous qualitative differential screening libraries. The usefulness of such libraries lies in that they include exclusively the whole range of introns transcribed in a given condition. Whether they hybridize with a probe derived from mature RNAs of a distinct condition allows one to quickly ascertain if the condition under study is characterized by persisting introns while providing for their easy identification.

Generally speaking, the libraries are generated by spreading, on a solid medium (notably on agar medium), of a cell culture transformed by the cloned nucleic acids. Transformation is done by any technique known to those skilled in the art (transfection, calcium phosphate precipitation, electroporation, infection with bacteriophage, etc.). The cell culture is generally a bacterial culture, such as for example *E. coli*. It may also be a eukaryotic cell culture, notably lower eukaryotic cells (yeasts for example). This spreading step can be performed in sterile conditions on a dish or any other suitable support. Additionally, the spread cultures on agar medium can be stored in a frozen state for example (in glycerol or any other suitable agent). Naturally, these libraries can be used to produce "duplicates", i.e. copies made according to common techniques more fully described hereinafter. Furthermore, such libraries are generally used to prepare an amplified library, i.e. a library comprising each clone in an amplified state. An amplified library is prepared as follows : starting from a spread culture, all cellular clones are recovered and packaged for storage in the frozen state or in a cold place, using any compatible medium. This amplified library is advantageously prepared from *E. coli* bacterial cultures, and is stored at 4°C, in sterile conditions. This amplified library allows preparation and unlimited replication of any subsequently prepared library containing such clones, on different supports, for a variety of applications. Such a

library further allows the isolation and characterization of any clone of interest. Each clone composing the libraries of the invention is indeed a characteristic element of a physiological condition, and constitutes therefore a particularly interesting target for various studies such as the search for markers, antibody production, diagnostics, gene transfer therapy, etc. These different applications are discussed in more detail below. The library is generally prepared as described above by spreading the cultures in an agar medium, on a suitable support (petri dish for example). The advantage of using an agar medium is that each colony can be separated and distinctly recognized. Starting from this culture, identical duplicates may be prepared in substantial amounts simply by replica-plating on any suitable support according to techniques known in the art. Thus, the duplicate may be obtained by means of filters, membranes (nylon, nitrocellulose, etc.) on which cell adhesion is possible. Filters may then be stored as such, at 4°C for example, in a dried state, in any packing medium that does not alter nucleic acids. Filters may equally be treated in such a manner as to discard cells, proteins, etc., and to retain only such components as nucleic acids. These treatment procedures may notably comprise the use of proteases, detergents, etc. Treated filters may be equally stored in any device or under any condition acceptable for nucleic acids.

The nucleic acid libraries can be equally directly prepared from nucleic acids, by transfer onto biochips or any other suitable device.

The invention is equally directed to any library comprising oligonucleotides specific of alternative splicing events that distinguish two physiological conditions. These are advantageously single stranded oligonucleotides comprising from 5 to 100-mers, preferably less than 50-mers, for example in the range of 25-mers.

These oligonucleotides are specific of alternative splicings representative of a given condition or type of physiological condition. Thus, such oligonucleotides may for example be oligonucleotides representative of alternative splicing events characteristic of apoptotic states. Indeed, it has been reported in the literature that certain alternative splicing events are observed in apoptotic conditions. This holds especially true for splicing within Bclx, Bax, Fas or Grb2 genes for example. By referring to published data or sequences available in the literature and/or in databases, it is possible to generate oligonucleotides specific to spliced or unspliced forms. These oligonucleotides may for example be generated according to the following strategy :

(a) identifying a protein or a splicing event characteristic of an apoptotic condition and the sequence of the spliced domain. This identification procedure can be based upon published data or a compilation of available sequences in databases;

5 (b) synthesizing artificially one or more oligonucleotides corresponding to one or more regions of this domain, which therefore allow the identification of the unspliced form in the RNAs of a test sample through hybridization ;

(c) synthesizing artificially one or more oligonucleotides corresponding to the junction region between two domains separated by the spliced domain. These  
10 oligonucleotides therefore allow the identification of the spliced form in the RNAs of a test sample through hybridization;

(d) repeating steps (a) to (c) listed above with other proteins or splicing events characteristic of apoptotic conditions ;

(e) transferring upon a first suitable support one or a plurality of  
15 oligonucleotides specific to apoptotic forms of messengers identified hereinabove and, upon another suitable support, one or a plurality of oligonucleotides specific to non-apoptotic forms.

The two supports thus obtained may be used to assess the physiological state of cells or test samples, and particularly their apoptotic state, through  
20 hybridization of a nucleic acid preparation derived from such cells or samples.

Other similar libraries can be generated using oligonucleotides specific to different pathophysiological states (neurodegeneration, toxicity, proliferation, etc.), thus broadening the range of applications.

Alternative intron or exon libraries can also be in the form of computerized  
25 data base systems compiled by systematically analyzing databases in which information about genomes of individual organisms, tissues or cell cultures is recorded. In such a case, the data obtained by elaboration of such virtual databases may be used to generate oligonucleotide primers that will serve in testing two pathophysiological conditions in parallel.

30 The computerized databases may further be used to derive versatile nucleotide probes, representative of a given class of proteins, or specific of a particular sequence. These probes can then be deposited on the clone libraries derived from different alternative intron and exon cloning techniques in order to appreciate the complexity of these molecular libraries and rapidly determine whether

a given class of protein or a given defined sequence is differentially spliced when comparing two distinct pathophysiological states.

A further nucleic acid composition or library according to the invention is an antisense library, generated from the sequences identified according to the methods of the invention (DATAS). To generate this type of library, such sequences are cloned so as to be expressed as RNA fragments corresponding to an antisense orientation relative to the messenger RNAs used for DATAS. This results in a so-called antisense library. This approach preferentially makes use of the cloning variant which allows orientation of the cloned fragments. The usefulness of such an antisense library is that it allows transfection of cell lines and monitoring of all phenotypic alterations whether morphological or enzymatic, or revealed by the use of reporter genes or genes that confer resistance to a selective agent. Analysis of phenotypic variations subsequent to the introduction of an antisense expression vector is generally done after selection of so-called stable clones, i.e. allowing coordinated replication of the expression vector and the host genome. This coordination is enabled through the integration of the expression vector into the cellular genome or, when the expression vector is episomal, through selective pressure. Such selective pressure is applied by treating the transfected cell culture with a toxic agent that can only be detoxified when the product of a gene carried by the expression vector is expressed within the cell. This results in synchronization between host and transgene replication. One advantageously uses episomal vectors derived from the Epstein-Barr virus which allow expression of 50 to 100 vector copies within a given cell (Deiss et al., (1996), EMBO J., 15: 3861-3870 ; Kissil et al., (1995), J. Biol. Chem., 270: 27932-27936).

The advantage of these antisense libraries related to the DATAS sequences they contain is that they not only allow identification of the gene the expression of which is inhibited to produce the selected phenotype, but also identification of which splicing isoform of this gene was affected. When the antisense fragment targets a given exon, it may be deduced therefrom that the protein domain and thus the function involving this domain counteracts the observed phenotype. In this respect coupling of DATAS with an antisense approach represents a shortcut towards functional genomics.

#### DNA chips

The invention is further directed to any support material (membrane, filter, biochip, chip, etc.) comprising a nucleic acid composition or library as defined hereinabove. This may more particularly be a cell library or a nucleic acid library. The invention also concerns any kit or support material comprising several libraries according to the invention. In particular, it may be advantageous to use in parallel a library representative of the qualitative features of a test physiological condition with respect to a reference physiological condition and, as control, a library representative of the features of a reference physiological condition in relation to the test physiological condition (a "library pair"). An advantageous kit according to the invention thus comprises two differential qualitative libraries belonging to two physiological conditions (a "library pair"). According to one particular embodiment, the kits pursuant to the invention comprise several library pairs as defined hereinabove, corresponding to distinct physiological states or to different biological samples for example. The kits may comprise for example these different library pairs arranged serially on a common support.

#### Generation of probes

Another use of the cDNA compositions according to the invention, representative of qualitative differences occurring between two pathophysiological states, consists in deriving probes thereof. Such probes may in fact be used to screen differential splicing events between two pathophysiological conditions.

These probes (see Figure 1D) may be prepared by labeling nucleic acid libraries or populations according to conventional techniques known in the art. Thus, the labeling may be carried out by enzymatic, radioactive, fluorescent, immunological means, etc. The labeling is preferably radioactive or fluorescent. This type of labeling may be accomplished for example by introducing into the nucleic acid population (either after synthesis or during synthesis) labeled nucleotides, enabling their visualization by conventional methods.

One application is therefore to screen a conventional genomic library. Such a library may comprise, depending on whether the vector is derived from a phage or a cosmid, DNA fragments of 10 kb to 40 kb. The number of clones hybridizing with the probes generated by DATAS and representative of differential splicing events occurring between two conditions thus approximately reflects the number of genes affected by alternative splicings, according to whether they are expressed in one or

the other condition being investigated.

Preferably, the probes of the invention are used to screen a genomic DNA library (generally of human origin) adapted to identifying splicing events. Such a genomic library is preferably composed of DNA fragments of restricted size (generally cloned into vectors), so as to yield statistically only a single differentially spliceable element, i.e. a single exon or a single exon. The genomic DNA library is therefore prepared by digesting genomic DNA with an enzyme having a recognition site restricted by 4 bases, thus providing the possibility of obtaining by controlled digestion DNA fragments with an average size of 1 kb. Such fragments require the generation of  $10^7$  clones to constitute a DNA library representative of a higher eukaryotic genome. Such a library is equally an object of the present application. This library is then hybridized with the probes derived from qualitative differential screening. In fact, for each experiment being investigated and which compares two pathophysiological conditions A and B, two probes (probe pair) are obtained. One probe is enriched in splicing events characteristic of condition A and one probe is enriched in splicing markers characteristic of B. Clones in the genomic library which hybridize preferentially with one of either probe harbor sequences that are preferentially spliced in the corresponding pathophysiological conditions.

The methods of the invention thus provide for the systematic identification of qualitative differences in gene expression. These methods have many applications, related to the identification and/or cloning of molecules of interest, in the fields of toxicology, pharmacology or still, in pharmacogenomics for example.

#### Applications

The invention is therefore additionally concerned with the use of the methods, nucleic acids or libraries previously described for identifying molecules of therapeutic or diagnostic value. The invention is more specifically concerned with the use of the methods, nucleic acids or libraries described hereinabove for identifying proteins or protein domains that are altered in a pathology.

One of the major strengths of these techniques is, indeed, the identification, within a messenger, and consequently within the corresponding protein, of the functional domains which are affected in a given disorder. This makes it possible to assess the importance of a given domain in the development and persistence of a pathological state. The direct advantage of restricting to a given protein domain the

impact of a pathological disorder resides in that the latter can be viewed as a relevant target for screening small molecules for therapeutic purposes. This information further constitutes a key for designing therapeutically active polypeptides that may be delivered by gene therapy; such polypeptides can notably be single chain antibodies derived from neutralizing antibodies directed against domains identified by the techniques herein described.

More specifically, the methods according to the invention provide molecules which :

- may be coding sequences derived from alternative exons.
- may correspond to noncoding sequences borne by introns differentially spliced between two pathophysiological states.

From these two points, different information can be obtained.

Alternative splicings of exons which discriminate between two pathophysiological states reflect a regulatory mechanism of gene expression capable of modulating (in more precise terms suppressing or restoring) one or a number of functions of a particular protein. Therefore, as the majority of structural and functional domains (SH2, SH3, PTB, PDZ, and catalytic domains of various enzymes) are encoded by several contiguous exons, two configurations might be considered :

i) the domains are truncated in the pathological condition (Zhu, Q. et al., (1994), J. Exp. Med., 180 (2): 461-470); this indicates that the signaling pathways involving such domains must be restored for therapeutical purposes.

ii) the domains are retained in the course of a pathological disorder whereas they are absent in the healthy state ; these domains can be considered as screening targets for low molecular weight compounds intended to antagonize signal transduction mediated by such domains.

The differentially spliced sequences may correspond to noncoding regions located 5' or 3' of the coding sequence or to introns occurring between two coding exons. In the noncoding regions, these differential splicings could reflect a modification of messenger stability or translatability (Bloom, T. J. and Beavo, J. A., (1995), Proc. Natl. Acad. Sci. USA, 93 (24): 14188-14192; Ambartsumian, N. et al., (1995), Gene, 159 (1): 125-130). A search for these phenomena should be conducted based on such information and might qualify the corresponding protein as a candidate target in view of its accumulation or disappearance. Retention of an



intron in a coding sequence often results in the truncation of the native protein by introducing a stop codon within the reading frame (Varesco, L., et al., (1994), *Hum. Genet.*, 93 (3): 281-286; Canton, H., et al., (1996), *Mol. Pharmacol.*, 50 (4): 799-807; Ion, A., et al., (1996), *Am. J. Hum. Genet.*, 58 (6): 1185-1191). Before such a stop codon is read, there generally occurs translation of a number of additional codons whereby a specific sequence is appended to the translated portion, which behaves as a protein marker of alternative splicing. These additional amino acids can be used to produce antibodies specific to the alternative form inherent to the pathological condition. These antibodies may subsequently be used as diagnostic tools. The truncated protein undergoes a change or even an alteration in properties. Thus enzymes may lose their catalytic or regulatory domain, becoming inactive or constitutively activated. Adaptors may lose their capacity to link different partners of a signal transduction cascade (Watanabe, K. et al., (1995), *J. Biol. Chem.*, 270 (23): 13733-13739). Splicing products of receptors may lead to the formation of receptors having lost their ability to bind corresponding ligands (Nakajima, T. et al., (1996), *Life Sci.*, 58 (9): 761-768) and may also generate soluble forms of receptor by release of their extracellular domain (Cheng J., (1994), *Science*, 263 (5154): 1759-1762). In this case, diagnostic tests can be designed, based on the presence of circulating soluble forms of receptor which bind a given ligand in different physiological fluids.

The invention is more specifically concerned with the use of the methods, nucleic acids or libraries described hereinabove for identifying antigenic domains that are specific for proteins involved in a pathology. The invention is equally directed to the use of the nucleic acids, proteins or peptides as described above for diagnosing pathological conditions.

The invention is equally directed to a method for identifying and/or producing proteins or protein domains involved in a pathology comprising :

(a) hybridizing messenger RNAs of a pathological sample with cDNAs of a healthy sample, or vice versa, or both in parallel,

(b) identifying, within the hybrids formed, regions corresponding to qualitative differences (unpaired (RNA) or paired (double stranded DNA)) which are specific to the pathological state in relation to the healthy state,

(c) identifying and/or producing the protein or protein domain corresponding to one or several regions identified in step (b).

The regions so identified generally correspond to differential splicings, but they may also correspond to other genetic alterations such as insertion(s) or deletion(s), for example.

The protein(s) or protein domains may be isolated, sequenced, and used in therapeutic or diagnostic applications, notably for antibody production.

To better illustrate this point, the qualitative differential screening of the invention allows one to advantageously identify tumor suppressor genes. Indeed, many examples indicate that one way suppressor genes are inactivated in the course of tumor progression is inactivation by modulation of alternative forms of splicing.

Hence, in small cell lung carcinoma, the gene of protein p130 belonging to the RB family (retinoblastoma protein) is mutated at a consensus splicing site. This mutation results in the removal of exon 2 and in the absence of synthesis of the protein due to the presence of a premature stop codon. This observation was the first of its kind to underscore the importance of RB family members in tumorigenesis. Likewise, in certain non small cell lung cancers, the gene of protein p16INK4A, a protein which is an inhibitor of cyclin-dependent kinases cdk4 and cdk6, is mutated at a donor splicing site. This mutation results in the production of a truncated protein with a short half-life, leading to the accumulation of the inactive phosphorylated forms of RB. Furthermore, WT1, the Wilms' tumor suppressor gene, is transcribed into several messenger RNAs generated by alternative splicings. In breast cancers, the relative proportions of different variants are modified in comparison to healthy tissue, thereby yielding diagnostic tools or clues to understanding the importance of the various functional domains of WT1 in tumor progression. The same alteration process affecting ratios between different messenger RNA forms and protein isoforms during cellular transformation is again found in the case of neurofibrin NF1. In addition, the concept that modulation of splicing phenomena behaves as a marker of tumor progression is further supported by the example of HDM2 where five alternative splicing events are detected in ovarian and pancreatic carcinoma, the expression of which increases depending on the stage of tumor development. Furthermore, in head and neck cancers, one of the mechanisms by which p53 is inactivated involves a mutation at a consensus splicing site.

These few examples clearly illustrate the interest of the methods of the invention based on systematic screening for alternative splicing patterns which

discriminate between a given tumor and an adjacent healthy tissue. Results thus obtained allow not only the characterization of known tumor suppressor genes but also, in view of the original and systematic aspect of qualitative differential screening methods, the identification of novel alternative splicings specific to tumors that are likely to affect new tumor suppressor genes.

The invention is therefore further directed to identifying and/or cloning tumor suppressor genes or genetic alterations (eg., splicing events) within those tumor suppressor genes, as previously defined. This method may advantageously comprise the following steps :

(a) hybridizing messenger RNAs of a tumor sample with cDNAs of a healthy sample, or vice versa, or both in parallel,

(b) identifying, within the hybrids formed, regions specific to the tumor sample in relation to the healthy sample,

(c) identifying and/or cloning the protein or protein domain corresponding to one or more regions identified in step (b).

The tumor suppressor properties of the proteins or protein domains identified may then be tested in different known models. These proteins, or their native forms (displaying the splicing pattern observed in healthy tissue) may then be use for various therapeutic or diagnostic applications, notably for antitumoral gene therapy.

The present application therefore relates not only to different aspects of embodying the present technology but also to the exploitation of the resulting information in research, development of screening assays for chemical compounds of low molecular weight, and development of gene therapy or diagnostic tools.

In this connection, the invention further concerns the use of the methods, nucleic acids or libraries described above in genotoxicology, i.e. to predict the toxicity of test compounds.

The genetic programs initiated during treatment of cells or tissues by toxic agents are predominantly correlated with apoptotic processes, or programmed cell death. The importance of alternative splicing processes in regulating such apoptotic mechanisms is well described in the literature. However, no single gene engineering technique described to date allows exhaustive screening and isolation of sequence variations due to alternative splicings distinctive of two given pathophysiological conditions. The qualitative differential splicing screening methods developed by the present invention make it possible to gather all splicing

differences occurring between two conditions within cDNA libraries. Comparing RNA sequences (for example messenger RNAs) of a tissue (or of a cell culture) either treated or not with a standard toxic compound allows the generation of cDNA libraries which comprise gene expression qualitative differences characterizing the toxic effect being investigated. These cDNA libraries may then be hybridized with probes derived from RNA arising from the same tissues or cells treated with the chemical being assessed for toxicity. The relative capacity of these probes to hybridize with the genetic sequences specific to a given standard toxic condition allows toxicity of the compound to be determined. Furthermore, in addition to the use of DATAS for the generation and utilization of qualitative differential libraries induced by toxic agents, a part of the invention consists equally in demonstrating that regulation defects in the splicing of certain messenger RNAs may be induced by certain toxic agents, at doses lower than the IC50 determined in the cytotoxicity and apoptosis tests known to those skilled in the art. Such regulation defects (or deregulations) may be used as markers to assess the toxicity and/or potency of molecules (chemical or genetic).

The invention therefore equally concerns any method for detecting or monitoring the toxicity and/or therapeutic potential of a compound based on the detection of splicing forms and/or patterns induced by this compound on a biological sample. It further concerns the use of any modification of splicing forms and/or patterns as a marker to assess the toxicity and/or potency of molecules.

Toxicity assessment or monitoring may be performed more specifically following two approaches :

According to a first approach, the qualitative differential screening may be accomplished between a reference tissue or cell culture not subjected to treatment on the one hand, and treated by the product whose toxicity is to be assessed on the other hand. The analysis of clones representative of qualitative differences specifically induced by this product subsequently provides for the eventual detection within these clones of events closely related to cDNA involved in toxic reactions such as apoptosis.

Such markers are monitored as they arise as a function of the dose and duration of treatment by the product in question so that the toxicological profile thereof may be established.

The present application is therefore equally directed to a method for

identifying, by means of qualitative differential screening according to the methods set forth above, toxicity markers induced in a model biological system by a chemical compound whose toxicity is to be measured. In this respect, the invention relates in particular to a method for identifying and/or cloning nucleic acids specific of a toxic state of a given biological sample comprising preparing qualitative differential libraries between the cDNAs and the RNAs of the sample either subjected or not to treatment by the test toxic compound, and searching for toxicity markers specific to the properties of the sample post-treatment.

According to the second approach, abacus are prepared for different classes of toxic products, that are fully representative of the toxicity profiles as a function of dosage and treatment duration for a given reference tissue or cell model. For each abacus dot, cDNA libraries representative of qualitative genetic differences can be generated. The latter represent qualitative differential libraries, i.e. they are obtained by extracting genetic information from the dot selected in the abacus diagram and from the corresponding dot in the control tissue or cell model. As set forth in the examples, the qualitative differential screening is based on hybridizing mRNA derived from one condition with cDNAs derived from another condition. As noted above, the qualitative differential screening may also be conducted using total RNAs or nuclear RNAs containing premessenger species.

In this respect, the invention concerns a method for determining or assessing the toxicity of a test compound to a given biological sample comprising hybridizing :

- differential libraries between cDNAs and RNAs of said biological sample from a healthy state and at various stages of toxicity resulting from treatment of said sample with a reference toxic compound, with,
- a nucleic acid preparation of the biological sample treated by said test compound, and
- assessing the toxicity of the test compound by determining the extent of hybridization with the different libraries.

According to this method, it is advantageous to proceed with two cross hybridizations for each condition (compound dosage and/or incubation time), between :

- RNAs from condition A (test) and cDNAs from condition B (reference) ( rA/cB)
- RNAs from condition B (reference) and cDNAs from condition A

(test) (rB/cA).

Each reference toxic condition, at each abacus dot, thus corresponds to two qualitative differential screening libraries. One of such libraries is a full collection of qualitative differences, i.e. notably the alternative splicing events, specific to the normal reference condition whereas the other library is a full collection of splicing events specific to the toxic situations. These libraries are replica-plated on solid support materials such as nylon or nitrocellulose filters or advantageously on chips. These libraries initially formed of cDNA fragments of variable length (according to the splicing events being considered) may be optimized by using oligonucleotides derived from previously isolated sequences.

Where a chemical compound is a candidate for pharmaceutical development, this may be tested with the same tissue or cell models as those recorded in the toxicity abacus diagram. Molecular probes may then be synthesized from mRNAs extracted from the biological samples treated with the chemical compound of interest. These probes are then hybridized on filters bearing cDNA of rA/cB and rB/cA libraries. For instance, the rA/cB library may contain sequences specific to the normal condition and the rB/cA library may contain alternative spliced species specific to the toxic condition. Innocuity or toxicity of the chemical compound is then readily assessed by examining the hybridization profile of an mRNA-derived probe belonging to the reference tissue or cell model that has been treated by the test compound :

- efficient hybridization with the rA/cB library and no signal in the rB/cA library demonstrates that the compound has no toxicity in the model under study

- positive hybridization between the probe and the rB/cA library clones is evidence of test compound-induced toxicity.

Practical applications related to such libraries may be provided by hepatocyte culture models, such as the HepG2 line, renal epithelial cells, such as the HK-2 line, or endothelial cells, such as the ECV304 line, following treatment by toxic agents such as ethanol, camptothecin or PMA.

A preferred example may be provided by use in cosmetic testing of skin culture models subjected or not to treatment by toxic agents or irritants.

A further object of the present application is therefore differential screening libraries (between cDNAs and RNAs) made from reference organs, tissues or cell

cultures treated by chemical compounds representative of broad classes of toxic agents according to abacus charts disclosed in the literature. The invention further encompasses the spreading of these libraries on filters or support materials known to those skilled in the art (nitrocellulose, nylon...). Advantageously, these support materials may be chips which hence define genotoxicity chips. The invention is further concerned with the potential exploitation of the sequencing data about different clones making up these libraries in order to understand the mechanisms underlying the action of various toxic agents, as well as with the use of such libraries in hybridization with probes derived from cells or tissues treated by a chemical compound or a pharmaceutical product whose toxicity is to be determined. Advantageously, the invention relates to nucleic acid libraries such as of the type defined above, prepared from skin cells treated under different toxic conditions. The invention is further concerned with a kit comprising these individual skin differential libraries.

The invention is further directed to the use of the methods, nucleic acids or libraries previously described to assess (predict) or enhance the therapeutic effectiveness of test compounds (genopharmacology).

In this particular use, the underlying principle is very similar to that previously described. Reference differential libraries are established between cDNAs and RNA from a control cell culture of organ and counterparts thereof simulating a pathological model. The therapeutic efficacy of a product may then be evaluated by monitoring its potential to antagonize qualitative variations of gene expression which are specific of the pathological model. This is demonstrated by a change in the hybridization profile of a probe derived from the pathological model with the reference libraries : in the absence of treatment, the probe only hybridizes with the library containing the specific markers of the disease. Following treatment with an effective product, the probe, though it is derived from the pathological model, hybridizes preferentially with the other library, which bears the markers of the healthy model equivalent.

In this respect, the model is further directed to a method for determining or assessing the therapeutic efficacy of a test compound on a given biological sample comprising hybridizing :

- differential libraries between cDNAs and RNAs from said biological sample in a healthy state and in a pathological state (at different development stages), with,

- a preparation of nucleic acids derived from the biological sample treated by said test compound, and

- assessing the therapeutic potential of the test compound by determining the extent of hybridization with the different libraries.

5 Such an application is exemplified by an apoptosis model simulating certain aspects of neurodegeneration which are antagonized by standard trophic factors. Thus, cells derived from the PC12 pheochromocytoma line which differentiate into neurites in the presence of NGF enter into apoptosis upon removal of this growth factor. This apoptotic process is accompanied by expression of many programmed  
10 cell death markers, several of which are regulated by alternative splicing and downregulated by IGF1. Two libraries derived from qualitative differential screening are generated from mRNA extracts of differentiated PC12 cells in the process of apoptosis following NGF removal on the one hand and from differentiated PC12 cells prevented from undergoing apoptosis by supplementing IGF-1 on the other  
15 hand. To these libraries, may be hybridized probes prepared from mRNA derived from differentiated PC12 in the process of apoptosis and whose survival is enhanced by treatment with a neuroprotective product to be tested. The efficiency of the test compound to reverse the qualitative characteristics can thus be appreciated by monitoring the capacity of the probe to selectively hybridize to those  
20 specific library clones representing cells having a better survival rate. This test could be subsequently used to test the efficiency of derivatives of such a compound or any other novel family of neuroprotective compounds and to improve the pharmacological profile thereof.

25 In a specific embodiment, the method of the invention allows one to assess the efficacy of a neuroprotective test compound by carrying out hybridization with a differential library according to the invention derived from a healthy nerve cell and this neurodegenerative model cell.

In another embodiment, one is interested in testing an antitumor compound using differential libraries established from tumor and healthy cell samples.

30 As already noted, the method of the invention could furthermore be used to improve the properties of a compound, by testing the capacity of various derivatives thereof to induce a hybridization profile similar to that of the library representative of the healthy sample.

The invention is further directed to the use of the methods, nucleic acids or



libraries described hereinabove in pharmacogenomics, i.e. to assess (predict) the response of a patient to a test compound or treatment.

Pharmacogenomics is aimed at establishing genetic profiles of patients with a view to determine which treatment would reasonably be successful for a given pathology. The techniques described in the present invention make it possible in this respect to establish cDNA libraries that are representative of qualitative differences occurring between a pathological condition which is responsive to a given treatment and another condition which is unresponsive or poorly responsive thereto, and thus may qualify for a different therapeutic strategy. Once these standard libraries are established, they can be hybridized with probes prepared from the patients' messenger RNAs. The hybridization results allow one to determine which patient has a hybridization profile corresponding to the responsive or non responsive condition and thus refine treatment choice in patient management.

In this application, the purpose is on the one hand to suggest depending on the patient's history the most appropriate treatment regimen likely to be successful and on the other hand to enroll in a given treatment regimen those patients most likely to benefit therefrom. As with other applications, two qualitative differential screening libraries are prepared : one based on a pathological model or sample known to respond to a given treatment, and another based on a further pathological model or sample which is poorly responsive or unresponsive to therapy. These two libraries are then hybridized with probes derived from mRNAs extracted from biopsy tissues of individual patients. Depending on whether such probes preferentially hybridize with the alternatively spliced forms specific to one particular condition, the patients may be divided into responsive and unresponsive subjects to the standard treatment which initially served to define the models.

In this respect, the invention is also directed to a method for determining or assessing the response of a patient to a test compound or treatment comprising hybridizing :

- differential libraries between cDNAs and RNAs from a biological sample responsive to said compound/treatment and from a biological sample which is poorly responsive or unresponsive to said compound/treatment, with,
- a nucleic acid preparation derived from a pathological biological sample of the patient, and
- assessing the responsiveness of the patient by determining the extent of

hybridization with the different libraries.

A preferred example of the usefulness of qualitative differential screening in pharmacogenomics is illustrated by a qualitative differential screening between two tumors of the same histological origin, one of which showing regression when treated with an antitumor compound (for example transfer of cDNA coding for wild type p53 protein by gene therapy), while the other being unresponsive to such treatment. The first benefit derived from constructing qualitative differential libraries between these two conditions is the ability to determine, by analyzing clones making up these libraries, which molecular mechanisms are elicited during regression as observed in the first model and absent in the second.

Subsequently, the use of filters or any other support material bearing cDNAs derived from these libraries allows one to conduct hybridization with probes derived from mRNAs of tumor biopsies whose response to said treatment is to be predicted. It is possible by looking at the results to assign patients to an optimized treatment regimen.

One particular example of this method consists in determining the tumor response to p53 tumor suppressor gene therapy. It has indeed been reported that certain patients and certain tumors respond more or less to this type of treatment (Roth et al., (1995) *Nature Medicine*, 2: 958). It is therefore essential to be able to determine which types of tumors and/or which patients are sensitive to wild type p53 gene therapy, in order to optimize treatment and make the best choice regarding the enrollment of patients in clinical trials being undertaken. Advantageously, the method of the invention makes it possible to simplify the procedure by providing libraries specific to qualitative characteristics of p53-responsive cells and non responsive cells. Examples of cell models sensitive or resistant to p53 are described for instance by Sabbatini et al. (*Genes Dev.*, (1995), 9: 2184) or by Roemer et al. (*Oncogene*, (1996), 12: 2069). Hybridization of these libraries with probes derived from patients' biopsy samples will make assessment of patient responsiveness easier. In addition, the specific libraries will allow identification of nucleic acids involved in p53 responsiveness.

The present application is therefore also directed to the establishment of differential screening libraries from pathological samples, or pathological models, which vary in responsiveness to at least one pharmacological agent. These libraries can be restricted, complex or autologous libraries as defined supra. It is also

concerned with the spreading of these libraries upon filters or support materials known to those skilled in the art (nitrocellulose, nylon...). In an advantageous manner, these support materials may be chips which thus define pharmacogenomic chips. The invention further relates to the potential exploitation of sequencing data of different clones forming such libraries with a view to elucidate the mechanisms which lead the pathological samples to respond differently to various treatments, as well as to the use of such libraries for conducting hybridization with probes derived from biopsy tissue originating from pathological conditions one wishes to predict the response to the standard treatment initially used to define those libraries.

The present invention thus describes that variations in splicing forms and/or patterns represent sources of pharmacogenomic markers, i.e. sources of markers by which to determine the capacity of and the manner in which a patient will respond to treatments. In this respect, the invention is thus further directed to the use of inter-individual variability in the isoforms generated by alternative splicing (spliceosome analysis) as a source of pharmacogenomic markers. The invention also concerns the use of splicing modifications induced by treatments as a source of pharmacogenomic markers. Thus, as explained hereinabove, the DATAS methods of the invention make it possible to generate nucleic acids representative of qualitative differences occurring between two biological samples. Such nucleic acids, or derivatives thereof (probes, primers, complementary acids, etc.) may be used to analyze the spliceosome of subjects, with a view to demonstrating their capacity and manner of responding to treatments, or their predisposition to a given treatment/pathology, etc.

These various general examples illustrate the usefulness of qualitative differential screening libraries in studies of genotoxicity, genopharmacology and pharmacogenomics as well as in research on potential diagnostic or therapeutic targets. Such libraries are derived from cloning the qualitative differences occurring between two pathophysiological situations. Since another use of the cDNAs representative of these qualitative differences is to generate probes designed to screen a genomic DNA library whose characteristics are described hereinabove, such an approach may also be implemented for any study of genotoxicity, genopharmacology and pharmacogenomics as well as for gene identification. In genotoxicity studies for instance, genomic clones statistically restricted by the size of their insertions to a single intron or to a single exon are arranged on filters according

to their hybridization with DATAS probes derived from qualitative differential analysis between a reference cell or tissue sample and the same cells or tissues treated by a reference toxic compound. Once such clones representative of different classes of toxicity are selected, they can then be hybridized with a probe derived from total messenger RNAs of a same cell population or a same tissue sample treated by a compound whose toxicity is to be assessed.

Other advantages and practical applications of the present invention will become more apparent from the following examples which are given for purposes of illustration and not by way of limitation. The fields of application of the invention are shown in Figure 7.

### LEGENDS TO FIGURES

Figure 1. Schematic representation of differential screening assays according to the invention (Figure 1A) using one (Figure 1B) or two (Figure 1C) hybridization procedures, and use of nucleic acids (Figure 1D).

Figure 2. Schematic representation of the production of RNA/DNA hybrids allowing characterization of single stranded RNA sequences, specific markers of the pathological or healthy state.

Figure 3. Schematic representation of a method for isolating and characterizing by sequencing single stranded RNA sequences specific to a pathological or healthy condition.

Figure 4. Schematic representation of another means for characterizing by sequencing all or part of the single stranded RNAs specific to a pathological or healthy condition.

Figure 5. Schematic representation of the isolation of alternatively spliced products based on R-loop structures.

Figure 6. Schematic representation of qualitative differential screening by loop restriction (formation of ds cDNA/cDNA homoduplexes and extraction of data, Figure 6A) and description of the data obtained (Figure 6B).

Figure 7. Benefits of qualitative differential screening at different stages of pharmaceutical research and development.

5 Figure 8. Isolation of a differentially spliced domain in the grb2/grb33 model.

A) Production of synthetic grb2 and grb33 RNAs. B) Description of the first steps of DATAS leading to characterization of an RNA fragment corresponding to a differentially spliced domain ; 1 : grb2 RNA, 2 : Hybridization between grb2 RNA and grb33 cDNA, 3 : Hybridization between grb2 RNA and grb2 cDNA, 4 : Hybridization  
10 between grb2 RNA and water, 5 : Supernatant after passage of (2) on streptavidin beads, 6 : Supernatant after passage of (3) on streptavidin beads, 7: Supernatant after passage of (4) on streptavidin beads, 8 : RNase H digestion of grb2 RNA / grb33 cDNA duplex, 9 : RNase H digestion of grb2 RNA / grb2 cDNA duplex, 10 : RNase H digestion of grb2 RNA, 11 : same as (8) after passage on an exclusion column, 12 : same as (9) after passage on an exclusion column, 13 : same as (10) after passage on an exclusion column.

Figure 9 . Representation of unpaired RNAs derived from RNase H digestion of RNA/single stranded cDNA duplexes originating from HepG2 cells treated or not  
20 by ethanol.

Figure 10 . Representation of double stranded cDNAs generated by one of the DATAS variants. 1 to 12 : PCR on RNA loop populations derived from RNase H digestion, 13 : PCR on total cDNA.

25 Figure 11. Application of the DATAS variant involving double stranded cDNA in the grb2/grb33 model. A) Agarose gel analysis of the complexes following hybridization : 1 : double stranded grb2 cDNA / grb33 RNA, 2 : double stranded grb2 cDNA / grb2 RNA, 3 : double stranded grb2 cDNA / water. B) Digestion of samples 1, 2 and 3 in (A) by nuclease S1 and mung bean nuclease : 1 to 3 : complexes 1 to 3 before glyoxal treatment ; 4 to 6 : complexes 1 to 3 after glyoxal treatment ; 7 to 9 : Nuclease S1 digestion of 1 to 3; 10 to 12 : Mung bean nuclease digestion of 1 to 3.

Figure 12. Application of the DATAS variant involving single stranded cDNA

and RNase H in a HepG2 cell system treated or not with 0.1 M ethanol for 18 hours. Cloned inserts were transferred to a membrane after agarose gel electrophoresis and hybridized with probes corresponding to the treated (Tr) and untreated (NT) conditions.

5

Figure 13. Experimental procedure for assessing the toxicity of a product.

Figure 14. Experimental procedure for monitoring the efficacy of a product.

10

Figure 15. Experimental procedure for investigating the sensitivity of a pathological condition to a treatment.

15

Figure 16. Analysis of differential hybridization of clones derived from DATAS using RNAs from induced cells and cDNAs from non-induced cells. A) Use of bacterial colonies deposited and lysed on a membrane. B) Southern blot on a selection of clones from A.

20

Figure 17. Nucleotide and peptide sequence of  $\Delta$ SHC (SEQ ID NO: 9 and 10).

Figure 18. Cytotoxicity and apoptosis tests on HepG2 cells treated with A) ethanol ; B) camptothecin ; C) PMA.

25

Figure 19. RT-PCR reactions using RNAs derived from HepG2 cells treated or not (NT) with ethanol (Eth.), camptothecin (Camp.) and PMA (PMA) allowing amplification of the fragments corresponding to MACH-a, BCL-X, FASR domains and using beta-actin as normalization control.

30

In the examples and the description of the invention, reference is made to sequences from the List of Sequences, which contains the following free text:

<223> OLIGO

<223> OLIGO

<223> OLIGO

<223> OLIGO

<223> OLIGO

<223> OLIGO

<223> OLIGO

<223> OLIGO

5 <223> OLIGO

<223> OLIGO

<223> OLIGO

<223> OLIGO

## 10 EXAMPLES

### 1. DIFFERENTIAL CLONING OF ALTERNATIVE SPLICINGS AND OTHER QUALITATIVE MODIFICATIONS IN RNAs USING SINGLE STRANDED cDNAs

Messenger RNAs corresponding to two conditions, one being normal (mN) and the other being of a pathological origin (mP), are isolated from biopsy samples or cultured cells. These messenger RNAs are converted into complementary DNAs (cN) and (cP) by means of reverse transcriptase (RT). mN/cP and cN/mP hybrids are then prepared in a liquid phase (see the diagram of Figure 2 illustrating one of either cases leading to the formation of cN/mP).

20 These hybrids are advantageously prepared in phenol emulsion (PERT technique or Phenol Emulsion DNA Reassociation Technique) continuously subjected to thermocycling (Miller, R.,D. and Riblet, R., (1995), Nucleic Acids Research, 23 (12): 2339-2340). Typically, this hybridization is executed using between 0.1 and 1 µg of polyA+ RNA and 0.1 to 2 µg of complementary DNA in an emulsion formed of an aqueous phase (120 mM sodium phosphate buffer, 2.5 M NaCl, 10 mM EDTA) and an organic phase representing 8 % of the aqueous phase and formed of twice distilled phenol.

30 Another method is also advantageously employed to obtain the heteroduplexes : after the reverse transcription reaction, the newly synthesized cDNA is separated from the biotinylated oligodT primer by exclusion chromatography. 0.1 to 2 µg of this cDNA is coprecipitated with 0.1 to 1 µg of polyA+ RNA in the presence of 0.3 M sodium acetate and two volumes of ethanol. These coprecipitated nucleic acids are taken up in 30 µl of a hybridization buffer composed of 80 % formamide, 40 mM PIPES (piperazinebis(2-ethanesulfonic acid))

pH 6.4, 0.4 M NaCl and 1 mM EDTA.

The nucleic acids in solution are heat-denatured at 85°C for 10 min and hybridization is then carried out at 40°C for at least 16 h and up to 48 h.

The advantage of the formamide hybridization procedure is that it provides  
5 more highly selective conditions for cDNA and RNA strand pairing.

As a result of these two hybridization techniques there is obtained an RNA/DNA heteroduplex the base pairing extent of which depends on the ability of RT to synthesize the entire cDNA. Other single stranded structures observed are RNA (and DNA) regions corresponding to alternative splicings which distinguish the  
10 two pathophysiological states under study.

The method is then aimed at characterizing the genetic information borne by such splice loops.

To this end, the heteroduplexes are purified by capture of cDNAs (primed with biotinylated oligo-dT) by means of streptavidin-coated beads. Advantageously  
15 these beads are beads having magnetic properties, allowing them to be separated from RNAs not engaged in the heteroduplex structures by the action of a magnetic separator. Such beads and such separators are commercially available.

At this stage of the procedure are isolated heteroduplexes and cDNAs not engaged in hybridization with RNAs. This material is then subjected to the action of  
20 RNase H which will selectively hydrolyze regions of RNA hybridized with cDNAs. The products of this hydrolysis are on the one hand cDNAs and on the other hand, RNA fragments which correspond to splice loops or non hybridized regions as a result of incomplete reverse transcriptase reaction. The RNA fragments are separated from DNA by magnetic separation according to the same experimental  
25 procedure as set forth above and by digestion with DNase free of contaminating RNase activity.

#### 1.1. Validation of the DATAS method on splicing variants of the Grb2 gene

The feasibility of this approach was demonstrated in an in vitro system using RNA corresponding to the coding region of Grb2 on the one hand and single  
30 stranded cDNA complementary to the coding region of Grb3.3. The Grb2 gene has an open reading frame of 651 base pairs. Grb33 is an isoform of grb2 generated by alternative splicing and comprising a deletion of 121 base pairs in the SH2 functional domain of grb2 (Fath et al., (1994), Science 264: 971-4). Grb2 and Grb33 RNAs are synthesized by methods known to those skilled in the art from a plasmid



harboring the Grb2 or Grb33 coding sequence driven by the T7 promoter by means of the RiboMax kit (Promega). Analysis of the products shows that the synthesis is homogeneous (Figure 8A). For purposes of visualization, Grb2 RNA was also radiolabeled by incorporation of a labeled base during in vitro transcription by means of the RiboProbe kit (Promega). Grb2 and Grb33 cDNAs were synthesized by reverse transcription from the above-obtained synthetic RNA products, using the Superscript II kit (Life Technologies) and a biotinylated oligonucleotide primer common to Grb2 and Grb33 corresponding to the complement of the Grb2 sequence (618-639). RNAs and cDNAs were treated according to the suppliers' instructions (Promega, Life Technologies), purified on an exclusion column (RNase-free Sephadex G25 or G50, 5 Prime, 3 Prime) and quantified by spectrophotometry.

The first steps of DATAS were executed by combining in suspension 10 ng of labeled Grb2 RNA with :

1. 100 ng of biotinylated grb33 cDNA,
2. 100 ng of biotinylated grb2 cDNA,
3. water

in 30  $\mu$ l of a hybridization buffer containing 80 % formamide, 40 mM PIPES (pH 6.4), 0.4 M NaCl, 1 mM EDTA. The nucleic acids are denatured by heating for 10 min at 85°C, after which the hybridization is carried out for 16 hours at 40°C. After capture on streptavidin beads, the samples are treated with RNase H as described hereinabove.

These steps are analyzed by electrophoresis on a 6 % acrylamide gel followed by processing of the gels with an Instant Imager (Packard Instruments) which allows the qualification and quantification of the species derived from labeled grb2 RNA (Figure 8B). Thus, lanes 2, 3 and 4 show that grb2/grb33 and grb2/grb2 duplexes are formed quantitatively. Migration of the grb2/grb33 complex is slower relative to that of grb2 RNA (lane 2) while that of the grb2/grb2 complex is faster (lane 3). Lanes 5, 6 and 7 correspond to samples not retained by the streptavidin beads showing that 80 % of grb2/grb33 and grb2/grb2 complexes were captured by the beads whereas non-biotinylated grb2 RNA alone was found solely in the bead supernatant. Treatment with RNase H releases, in addition to free nucleotides which migrate faster than bromophenol blue (BPB), a species that migrates below xylene cyanol blue (XC) (indicated by an arrow in the figure) and this, specifically in lane 8 corresponding to the grb2/grb33 complex relative to lanes 9 and 10 which

correspond to the grb2/grb2 complex and to grb2 RNA. Lanes 11, 12 and 13 correspond to lanes 8, 9 and 10 after passage of the samples through an exclusion column to remove free nucleotides. The migration observed in lanes 8 and 11 is that expected for an RNA molecule corresponding to the 121-nucleotide deletion that distinguishes grb2 from grb33.

This result clearly shows that it is possible to obtain RNA loops generated by the formation of heteroduplexes between two sequences derived from two splicing isoforms.

### 1.2. Application of the DATAS method to generate qualitative libraries of hepatic cells in a healthy and toxic state

A more complex situation was examined. Within the scope of the application of DATAS technology as a tool to predict the toxicity of molecules, the human hepatocyte cell line HepG2 was treated with 0.1 M ethanol for 18 hours. RNAs were extracted from cells that were or were not subjected to treatment. The aforementioned DATAS variant (preparation of biotinylated ss cDNA, cross hybridizations in liquid phase, application of a magnetic field to separate the species, RNase H digestion) was effected with untreated cells in the reference condition (or condition A) and with treated cells in the test condition (or condition B) (Figure 9). As the extracted RNAs were not radiolabeled, the RNAs generated by RNase H digestion were visualized by carrying out an exchange reaction to replace the RNA 5' phosphate with a labeled phosphate, by means of T4 polynucleotide kinase and gamma-P<sup>32</sup>ATP. These labeled products were then loaded on an acrylamide/urea gel and analyzed by exposure using an Instant Imager (Packard Instruments). Complex signatures derived from A/B and B/A hybridizations could then be visualized with a first group of signals migrating slowly in the gel and corresponding to large nucleic acid sequences and a second group of signals migrating between 25 and 500 nucleotides. These signatures are of much lower intensity in condition A/A, suggesting that ethanol can induce a reprogramming of RNA splicing events, manifested as the presence of A/B and B/A signals.

### 1.3. Cloning and preparation of libraries from the identified nucleic acids

Several experimental alternatives may then be considered to clone these RNA fragments resistant to the action of RNase H :

A. A first approach consists in isolating and cloning such loops (Figure 3).

According to this approach, one proceeds with ligation of oligonucleotides to

each end by means of RNA ligase according to conditions known in the art. These oligonucleotides are then used as primers to effect RT PCR. The PCR products are cloned and screened with total complementary DNA probes corresponding to the two pathophysiological conditions of interest. Only those clones preferentially hybridizing with one of either probes contain the splice loops which are then sequenced and/or used to generate libraries.

B. The second approach (Figure 4) consists in carrying out a reverse transcription reaction on single stranded RNA released from the heteroduplex structures by RNase H digestion, initiated by means of at least partly random primers. Thus, these may be primers with random 3' and 5' sequences, primers with random 3' ends and defined 5' sequences, or yet semi-random oligonucleotides, i.e. comprising a region of degeneration and a defined region.

According to this strategy, the primers may therefore hybridize either anywhere along the single stranded RNA, or at each succession of bases determined by the choice of semi-random primer. PCR is then run using primers corresponding to the above-described oligonucleotides in order to obtain splice loop-derived sequences.

Figure 10 (lanes 1 to 12) presents the acrylamide gel analysis of the PCR fragments obtained in several DATAS experiments and coupled to the use of the following semi-random oligonucleotides:

GAGAAGCGTTATNNNNNNNAGGT (SEQ ID NO: 1, X=T)

GAGAAGCGTTATNNNNNNNAGGA (SEQ ID NO: 1, X=A)

GAGAAGCGTTATNNNNNNNAGGC (SEQ ID NO: 1, X=C)

GAGAAGCGTTATNNNNNNNAGGG (SEQ ID NO: 1, X=G)

Comparing these results with the complexity of the signals obtained using the same oligonucleotides, but with total cDNA as the template (lane 13), demonstrates that DATAS makes it possible to filter (profile) the information corresponding to qualitative differences.

This variant was used to clone an event corresponding to the *grb2* RNA domain generated by RNase H digestion of the *grb2* RNA/*grb33* single stranded cDNA duplex according to the above-described protocol (example 1.1). To do so, an oligonucleotide with the sequence : GAGAAGCGTTATNNNNNNNTCCC (SEQ ID NO: 2), chosen from the model GAGAAGCGTTATNNNNNNNWXYZ (where N is defined as above, W, X and Y each represent a defined fixed base, and Z

designates either a defined base, or a 3'-OH group, SEQ ID NO: 3) and selected so as to amplify a fragment in the grb2 deletion, was used, allowing generation of a PCR fragment which, after cloning and sequencing, was shown to indeed be derived from the grb2 deleted domain (194-281 in grb2).

5        These two approaches therefore allow the production of nucleic acid compositions representative of the differential splicings in both conditions being tested, which may be used as probes or to construct qualitative differential cDNA libraries. The capacity of DATAS technology to generate profiled cDNA libraries representative of qualitative differences is further illustrated in example 1.4 below.

#### 10        1.4. Production of profiled libraries representative of human endothelial cells

This example was carried out using a human endothelial cell line (ECV304). The qualitative analysis of gene expression was achieved by using cytosolic RNA extracted from growing cells, on the one hand, and from cells in the process of anokis (apoptosis induced by removing the adhesion support), on the other hand.

15        ECV cells were grown in 199 medium supplemented with Earle salts (Life Sciences). Anokis was induced by passage for 4 hours on polyHEMA-treated culture dishes. For RNA preparation, cells were lysed in a buffer containing Nonidet P-40. Nuclei are then eliminated by centrifugation. The cytoplasmic solution was then adjusted so as to specifically fix the RNA to the Rneasy silica matrix according to the instructions of the Quiagen company. After washing, total RNA is eluted in DEPC-treated water. Messenger RNAs are prepared from total RNAs by separation on Dynabeads oligo (dT)<sub>25</sub> magnetic beads (Dyna). After suspending the beads in a fixation buffer, total RNA is incubated for 5 min at room temperature. After magnetic separation and washing, the beads are taken up in elution buffer and  
20        incubated at 65°C to release messenger RNAs.

25        The first DNA strand is synthesized from the messenger RNA by means of SuperScript II or ThermoScript reverse transcriptase (Life Technologies) and oligo-(dT) primers. After RNase H digestion, free nucleotides are eliminated by passage through a Sephadex G50 (5 Prime- 3 Prime) column. Following phenol/chloroform extraction and ethanol precipitation, samples are quantified by UV absorbance.

30        The required quantities of RNA and cDNA (in this case 200 ng of each) are pooled and ethanol-precipitated. The samples are taken up in a volume of 30 µl in hybridization buffer (40 mM Hepes (pH 7.2), 400 mM NaCl, 1 mM EDTA) supplemented with deionized formamide (80% (v/v), except if otherwise indicated).

After denaturation for 5 min at 70°C, samples are incubated overnight at 40°C.

The streptavidin beads (Dynal) are washed then reconditioned in fixation buffer (2X= 10 mM Tris-HCl (pH 7.5), 2 M NaCl, 1 mM EDTA). The hybridization samples are diluted to a volume of 200 µl with water, then adjusted to 200 µl of beads and incubated for 60 min at 30°C. After magnetic capture and washing of the beads, the latter are suspended in 150 µl of RNase H buffer then incubated for 20 min at 37°C. After magnetic capture, nonhybridized regions are released into the supernatant which is treated with Dnase, then extracted with acidic phenol/chloroform and ethanol-precipitated. Ethanol precipitations of small quantities of nucleic acids are carried out using a commercial polymer SeeDNA (Amersham Pharmacia Biotech) allowing quantitative recovery of nucleic acids from very dilute solutions (in the ng/ml range).

Synthesis of cDNA from the RNA samples derived from RNase H digestion is carried out by means of random hexanucleotides and Superscript II reverse transcriptase. The RNA is then digested with a mixture of RNase H and RNase T1. The primer, the unincorporated nucleotides and the enzymes are separated from the cDNA by means of a GlassMAX Spin cartridge. The cDNA corresponding to splice loops is then subjected to PCR using the semi-random oligonucleotides described hereinabove in the invention. In this case the chosen oligonucleotides are as follows :

GAGAAGCGTTATNNNNNCCA (SEQ ID NO: 4)

The PCR reaction is effected using Taq Polymerase for 30 cycles :

- Initial denaturation : 94°C for 1 min.
- 94°C for 30 s
- 55°C for 30 s
- 72°C for 30 s
- Final elongation : 72°C for 5 min.

The PCR products are cloned into the pGEM-T vector (Promega) with a floating T at the 3' ends so as to simplify cloning of the fragments derived from the activity of Taq polymerase. After transformation in competent JM109 bacteria (Promega), the resulting colonies are transferred to nitrocellulose filters, and hybridized with probes derived from the products of PCR carried out on total cDNA from growing cells on the one hand and in anoikis on the other hand. The same oligonucleotides GAGAAGCGTTATNNNNNCCA are used for these PCR

reactions. In a first experimental embodiment, 34 clones preferentially hybridizing with the probe from cells in apoptosis and 13 clones preferentially hybridizing with the probe from growing cells were isolated.

Among these 13 clones, 3 clones contain the same cDNA fragment derived from the SH2 domain of the SHC protein.

This fragment has the following sequence :

CCACACCTGGCCAGTATGTGCTCACTGGCTTGAGAGTGGGCAGCCAG  
CCTAAGCATTTCGACTGG (SEQ ID NO: 5)

The use of PCR primers flanking the SHC SH2 domain (5' oligo : GGGACCTGTTTGACATGAAGCCC (SEQ ID NO:6) ; 3' oligo : CAGTTTCGCTCCACAGTTGC (SEQ ID NO:7)) allowed characterization of the SHC SH2 domain deletion which is specifically observed in ECV cells in anoikis. With this primer pair, a single amplification product corresponding to a 382 base pair cDNA fragment which contains the intact SH2 domain is obtained from RNA from exponentially growing ECV cells. A further 287 base pair fragment is observed when the PCR is carried out with RNA from cells in anoikis. This additional fragment derives from a messenger RNA derived from the SCH messenger but with a deletion.

This deletion has the following sequence :

GTACGGGAGAGCACGACCACACCTGGCCAGTATGTGCTCACTGGCTTG  
CAGAGTGGGCAGCCTAAGCATTGCTACTGGTGGACCTGAGGGTGTG (SEQ  
ID NO: 8).

This deletion corresponds to bases 1198 to 1293 of the messenger open reading frame encoding the 52 kDa and 46 kDa forms of the SHC protein (Pelicci, G. et al., (1992), Cell, 70: 93-104).

Structural data on the SH2 domains together with the literature indicate that such a deletion leads to the loss of affinity for phosphotyrosines since it encompasses the amino acids involved in interactions with phosphorylated tyrosines (Waksman, G. et al., (1992), Nature, 358: 646-653). As SHC proteins are adaptors which link different partners via their SH2 and PTB domains (PhosphoTyrosine Binding domain), this deletion therefore generates a native negative dominant form of SHC which we call  $\Delta$ SHC. As the SH2 domains of proteins for which the genes have been sequenced are carried on two exons, it is likely that the deletion identified by DATAS corresponds to an alternative exon of the

SHC gene.

The protein and nucleic acid sequences of  $\Delta$ SHC are given in Figure 17 (SEQ ID NO: 9 and 10).

As the SHC SH2 domain is involved in the transduction of numerous signals involved in cell proliferation and viability, examination of the  $\Delta$ SHC sequence makes it possible to predict its negative dominant properties on the SHC protein and its capacity to interfere with various cellular signals.

The invention equally concerns this new spliced form of SHC, the protein domain corresponding to the splicing, any antibody or nucleic acid probe allowing its detection in a biological sample, and their use for diagnostic or therapeutic purposes, for example.

The invention particularly concerns any SHC variant comprising at least one deletion corresponding to bases 1198 to 1293, more particularly a deletion of sequence SEQ ID NO: 8. The invention more specifically concerns the  $\Delta$ SHC variant possessing the sequence SEQ ID NO: 9, coded by the sequence SEQ ID NO: 10.

The invention therefore concerns any nucleic acid probe, oligonucleotide or antibody by which to identify the hereinabove  $\Delta$ SHC variant, and/or any alteration of the SHC/ $\Delta$ SHC ratio in a biological sample. This may notably be a probe or oligonucleotide complementary to all or part of the sequence SEQ ID NO: 8, or an antibody directed against the protein domain encoded by this sequence. Such probes, oligonucleotides or antibodies make it possible to detect the presence of the nonspliced form (eg., SHC) in a biological sample.

The materials may further be used in parallel with the probes, oligonucleotides and/or antibodies specific of the spliced form (eg.,  $\Delta$ SHC), i.e. corresponding for example to the junction region resulting from splicing (located around nucleotide 1198 in sequence SEQ ID NO: 10).

Such materials may be used for the diagnosis of diseases related to immune suppression (cancer, immunosuppressive therapy, AIDS, etc.).

The invention also concerns any screening method for molecules based on blocking (i) the spliced domain in the SHC protein (especially in order to induce a state of immune tolerance for example in autoimmune diseases or graft rejection and cancer) or (ii) the added functions acquired by the  $\Delta$ SHC protein.

The invention is further directed to the therapeutic use of  $\Delta$ SHC, and notably

to the treatment of cancerous cells or cancers (ex vivo or in vivo) in which SHC protein hyperphosphorylation can be demonstrated, for example. In this respect, the invention therefore concerns any vector, notably a viral vector, comprising a sequence coding for  $\Delta$ SHC. This vector is preferably capable of transfecting cancerous or growing cells, such as smooth muscle cells, endothelial cells (restenosis), fibroblasts (fibrosis), preferably of mammalian, notably human, origin. Viral vectors may be exemplified in particular by adenoviral, retroviral, AAV, herpes vectors, etc.

## 2. DIFFERENTIAL CLONING OF ALTERNATIVE SPLICINGS AND OTHER QUALITATIVE MODIFICATIONS OF RNA USING DOUBLE STRANDED cDNA (FIGURE 5).

Messenger RNAs corresponding to normal (mN) and pathological (mP) conditions are produced, as well as corresponding double stranded complementary DNAs (dsN and dsP) by standard molecular biology procedures. R-loop structures are then obtained by hybridizing mN with dsP and mP with dsN in a solution containing 70 % formamide. Differentially spliced nucleic acid domains between conditions N and P will remain in the form of double stranded DNA. Displaced single stranded DNAs are then treated with glyoxal to avoid further displacement of the RNA strand upon removal of formamide. After removal of formamide and glyoxal and treatment with RNase H, there are obtained bee-type structures, the unpaired single stranded DNAs being representative of the bee wings and the paired double stranded domain of interest being reminiscent of the bee's body. The use of enzymes which specifically digest single stranded DNA such as nuclease S1 or mung bean nuclease allows the isolation of DNA that has remained in double stranded form, which is next cloned and sequenced. This second technique allows for direct formation of a double stranded DNA fingerprint of the domain of interest, when compared to the first procedure which yields an RNA fingerprint of this domain.

This approach was carried out on the grb2/grb33 model described above. Grb2 double stranded DNA was produced by PCR amplification of grb2 single stranded cDNA using two nucleotide primers corresponding to the sequence (1-22) of grb2 and to the complementary sequence (618-639) of grb2. This PCR fragment was purified on an agarose gel, cleaned on an affinity column (JetQuick, Genomed) and quantified by spectrophotometry. At the same time, two synthetic RNAs



corresponding to the *grb2* and *grb33* reading frames were produced from plasmid vectors harboring *grb2* or *grb33* cDNAs under the control of the T7 promoter, by means of the RiboMax kit (Promega). The RNAs were purified as instructed by the supplier and cleaned on an exclusion column (Sephadex G50, 5 prime-3 prime).

5 600 ng of double stranded *grb2* DNA (1-639) were combined with :

1. 3  $\mu$ g of *grb33* RNA
2. 3  $\mu$ g of *grb2* RNA
3. water

in three separate reactions, in the following buffer :

10 100 mM PIPES (pH 7.2), 35 mM NaCl, 10 mM EDTA, 70% deionized formamide (Sigma).

The samples were heated to 56°C, then cooled to 44°C by -0.2°C increments every 10 minutes. They are then stored at 4°C. Analysis of the agarose gel reveals the altered migration patterns of lanes 1 and 2 as compared with the control lane 3 (Figure 11A), indicating that new complexes were formed. Samples are then treated with deionized glyoxal (Sigma) (5% v/v or 1 M) for 2 h at 12°C. The complexes are then precipitated with ethanol (0.1 M NaCl, 2 volumes of ethanol), washed with 70% ethanol, dried, then resuspended in water. They are next treated by RNase H (Life Technologies), then by an enzyme specific for single stranded DNA. Nuclease S1 and mung bean nuclease have such a property and are commercially available (Life Technologies, Amersham). Such digestions (incubations for 5 minutes in the buffers supplied with the enzymes) were analyzed on agarose gels (Figure 11B). Significant digest products were obtained only from the complexes derived from reaction 1 (*grb2/grb33*) (Figure 11B, lanes 7 and 10). 15 These digestions appear more complete with nuclease S1 (lane 7) than with mung bean nuclease (lane 10). Thus, the band corresponding to a size slightly greater than 100 base pairs (indicated by an arrow on lane 7) was purified, cloned into the pMos-Blue vector (Amersham) and sequenced. This fragment corresponds to the 120 base pair domain of *grb2* which is deleted in *grb33*.

30 This approach may now be implemented starting with a total messenger RNA population and a total double stranded cDNA population produced according to methods known to those skilled in the art. RNAs corresponding to the reference condition are hybridized with double stranded cDNAs derived from the test condition and vice versa. After application of the hereinabove protocol, the digests are loaded

on agarose gels so as to isolate and purify the bands corresponding to sizes ranging from 50 to 300 base pairs. Such bands are then cloned in a vector (pMos-Blue, Amersham) to generate a library of inserts enriched in qualitative differential events.

### 3. CONSTRUCTION OF LIBRARIES DERIVED FROM QUALITATIVE 5 DIFFERENTIAL SCREENING

The two examples described hereinabove lead to the cloning of cDNAs representative of all or part of differentially spliced sequences occurring between two given pathophysiological conditions. These cDNAs allow the construction of libraries by insertion of such cDNAs into plasmid or phage vectors. These libraries  
10 may be deposited on nitrocellulose filters or any other support material known in the art, such as chips or biochips or membranes. The aforementioned libraries may be stored in a cold place, away from light. These libraries, once deposited and fixed on support materials by conventional techniques, may be treated by compounds to eliminate the host bacteria which allowed the replication of the plasmids or phages.  
15 These libraries may also be advantageously composed of cDNA fragments corresponding to cloned cDNAs but prepared by PCR so as to deposit on the filter only those sequences derived from alternative splicing events.

One of the features as well as one of the original characteristics of qualitative differential screening is that this method advantageously leads to not only one but  
20 two differential libraries ("library pair") which represent the whole array of qualitative differences occurring between two given conditions. In particular, one of the differential splicing libraries of the invention represents the unique qualitative markers of the test physiological condition as compared to the reference physiological condition, while the other library represents the unique qualitative  
25 markers of the reference physiological condition in relation to the test physiological condition. This couple of libraries is equally termed a library pair or "differential splicing library".

As one of the benefits of qualitative differential screening is that it makes it possible to assess the toxicity of a compound, as will be set forth in the next section,  
30 a good example of the implementation of the technology is the use of DATAS to obtain cDNA clones corresponding to sequences specific of untreated HepG2 cells, on the one hand, and ethanol-treated cells, on the other hand. The latter cells exhibit signs of cytotoxicity and DNA degradation via internucleosomal fragmentation starting from 18 hours of exposure to 1 M ethanol. In order to obtain

early markers of ethanol toxicity, messenger RNAs were prepared from untreated cells and from cells treated with 0.1 M ethanol for 18 h. After execution of the DATAS variant which makes use of single stranded cDNA and RNase H, the resulting cloned cDNAs were amplified by PCR, electrophoresed on agarose gels and then transferred to a nylon filter according to techniques known to those skilled in the art. For each set of clones specific on the one hand of specific qualitative differences of the untreated state and on the other hand of sequences specific of ethanol-treated cells, two identical filter duplicates are prepared. Thus the fingerprints of each set of clones are hybridized on the one hand with a probe specific to untreated cells and on the other hand with a probe specific to cells treated with 0.1 M ethanol for 18 h.

The differential hybridization profile obtained and shown in Figure 12 makes it possible to appreciate the quality of the subtraction afforded by the DATAS technique. Thus the clones derived from hybridization of mRNA from untreated cells (NT) with cDNA from treated cells (Tr) and which should correspond to qualitative differences specific of the untreated condition, hybridize preferentially with a probe representing the total messenger RNA population of untreated cells. Conversely, clones derived from products resistant to the action of RNase H on RNA(Tr)/cDNA(NT) heteroduplexes hybridize preferentially with a probe derived from total messenger RNAs from treated cells.

The two sets of clones specific on the one hand to the treated condition and on the other hand to the untreated condition represent an example of qualitative differential libraries characteristic of two distinct cell states.

#### 4. USES AND BENEFITS OF QUALITATIVE DIFFERENTIAL LIBRARIES.

The potential applications of the differential splicing libraries of the invention are illustrated notably in Figures 13 to 15. Thus, these libraries are useful for :

##### 4.1. Evaluating the toxicity of a compound (Figure 13) :

In this example, the reference condition is designated A and the toxic condition is designated B. Toxicity abacus charts are obtained by treating condition A in the presence of various concentrations of a reference toxic compound, for different periods of time. For different dots of toxicity abacus charts, qualitative differential libraries are constructed (library pairs), namely in this example, restricted libraries rA/cB and rB/cA. The library pairs are advantageously deposited on a support. The support is then hybridized with probes derived from the original

biological sample treated with different doses of test compounds : products X, Y and Z. The hybridization reaction is developed in order to determine the toxicity potential of the test products : in this example, product Z is highly toxic and product Y shows an intermediate profile. The feasibility of constructing toxicity abacus charts is clearly illustrated in the aforementioned example regarding the construction of qualitative differential screening libraries involving ethanol treatment and HepG2 cells.

#### 4.2. Assessing the potency of a pharmaceutical composition (Figure 14) :

In this example, a restricted library pair according to the invention is constructed starting with a pathological model B and a healthy model A (or a pathological model treated with a reference active product). The differential libraries rA/cB and rB/cA are optionally deposited on a support. This library pair is fully representative of the differences in splicing which occur between both conditions. This library pair allows the efficacy of a test compound to be assessed, i.e. to determine its capacity to generate a "healthy-like" profile (rA/cB) starting from a pathological-type profile (rB/cA). In this example, the library pair is hybridized with probes prepared from conditions A and B either treated or not by the test compound. The hybridization profile that can be obtained is shown in Figure 14. The feasibility of this application is identical to that of the aforementioned construction of qualitative differential libraries characteristic of healthy and toxic conditions. The toxic condition is replaced by the pathological condition and one assesses the capacity of a test compound to produce a probe hybridizing more or less preferentially with the reference or pathological conditions.

#### 4.3. Predicting the response of a pathological sample to a treatment (Figure 15) :

In this example, a restricted library pair according to the invention is constructed starting with two pathological models, one of which is responsive to treatment with a given product (the wild type p53 gene for example) : condition A ; while the other being unresponsive : condition B. This library pair (rA/cB ; rB/cA) is deposited on a support.

This library pair is then used to determine the sensitivity of a pathological test sample to the same product. For that purpose, this library pair is hybridized with probes derived from patients' biopsy tissues one wishes to evaluate the response to

the reference treatment. The hybridization profile of a responsive biopsy sample and of an unresponsive biopsy sample is presented in Figure 15.

#### 4.4 Identification of ligands for orphan receptors

The activation of membrane or nuclear receptors by their ligands can specifically induce regulation defects in the splicing of certain RNAs. Identification of these events by the DATAS methods of the invention provides a tool (markers, libraries, kits, etc.) by which to monitor receptor activation, which can be used to search for natural or synthetic ligands for receptors, especially orphan receptors. According to this application, markers associated with regulation defects are identified and deposited on supports. Total cellular RNA, (over)expressing the receptor under study, treated or not by different compositions and/or test compounds, is extracted and used as probe in a hybridization reaction with the supports. Detection of hybridization with some or even all of the markers deposited on the support, indicates that the receptor of interest was activated, and therefore that the corresponding composition/compound constitutes or contains the ligand of said receptor.

#### 4.5 Identification of targets of therapeutic interest :

This is accomplished by identifying genes the splicing of which is altered in a pathology or in a pathological model and more specifically by identifying the modified exons or introns. This approach should make it possible to determine the sequences which code for functional domains that are altered in pathologies or in any pathophysiological process involving the phenomena of growth, differentiation or apoptosis for example.

An example of the benefit of qualitative differential screening for identifying differentially spliced genes is provided by the application of DATAS to a model of apoptosis induction via induction of wild type p53 expression. This cellular model was established by transfecting an inducible p53 tumor suppressor gene expression system. In order to identify qualitative differences which are specifically associated with p53-induced apoptosis, DATAS was implemented starting with messenger RNAs derived from induced and non-induced cells. For these experiments 200 ng of polyA<sup>+</sup> RNA and 200 ng of cDNA were used for heteroduplex formation. About 100 clones were obtained from each cross hybridization. Hybridization of these bacterial clones, then of the cDNA fragments they contain, with probes representative of total messenger RNAs from the original conditions allowed identification of sequences

specifically expressed during the potent p53 induction which leads to cell death (Figure 16).

These fragments derive from exon or intron sequences which modulate the quality of the message present and qualify the functional domains in which they participate or which they interrupt, as targets for treatment to induce or to inhibit cell death.

Such an approach equally leads to the construction of a library pair comprising all the differential splicing events between a non-apoptotic condition and an apoptotic condition. This library pair may be used to test the hybridizing capacity of a probe derived from another pathophysiological condition or a given treatment. The results of such a hybridization will give an indication as to the potential commitment of the gene expression program of the test condition towards apoptosis.

As is apparent from the above description, the invention is further concerned with :

- any nucleic acid probe, any oligonucleotide, any antibody which recognizes a sequence identified by the method described in the present application and characterized in that they are characteristic of a pathological condition,

- the use of information derived from applying the techniques disclosed herein for the search of organic molecules for therapeutic purposes by devising screening assays characterized in that they target differentially spliced domains occurring between a healthy and a pathological condition or else characterized in that they are based on the inhibition of functions acquired by the protein as a result of differential splicing,

- the utilization of the information derived from the methods described in the present application for gene therapy applications,

- the use of cDNAs delivered by gene therapy, wherein said cDNAs behave as antagonists or agonists of defined cell signal transduction pathways,

- any construction or any use of molecular libraries of alternative exons or introns for purposes of :

- . commercial production of diagnostic means or reagents for research purposes

- . generation or search of molecules, polypeptides, nucleic acids for therapeutical applications.

- any construction or any use of all computerized virtual libraries containing an array of alternative exons or introns characterized in that said libraries allow the design of nucleic acid probes or oligonucleotide primers in order to characterize alternative splicing forms which distinguish two different pathophysiological conditions.
- any pharmaceutical or diagnostic composition comprising polypeptides, sense or antisense nucleic acids or chemical compounds capable of interfering with alternative splicing products identified and cloned by the methods of the invention,
- any pharmaceutical or diagnostic composition comprising polypeptides, sense or antisense nucleic acids, or chemical compounds capable of restoring a splicing pattern representative of a normal condition in contrast to an alternative splicing event inherent to a pathological condition.

## 5. DEREGULATIONS OF RNA SPLICING MECHANISMS BY TOXIC COMPOUNDS

This example shows that differential splicing forms and/or profiles may be used as markers to monitor and/or determine the toxicity and/or the efficacy of compounds.

- The effects of toxic compounds on RNA splicing regulation defects were tested as follows. HepG2 hepatocyte cells were treated with different doses of three toxic compounds (ethanol, camptothecin, PMA (phorbol 12-myristate 13-acetate)). Two cytotoxicity tests (trypan blue, MTT) were performed at different time points : 4 h and 18 h for ethanol ; 4 h and 18 h for camptothecin ; 18 h and 40 h for PMA.

- Trypan blue is a dye that can be incorporated by living cells. Simple counting of "blue" and "white" cells under a microscope gives the percentage of living cells after treatment or the percentage of survival. The experimental points are determined in triplicate.

- The MTT test is a colorimetric test measuring the capacity of living cells to convert soluble tetrazolium salts (MTT) into an insoluble formazan precipitate. These dark blue formazan crystals can be dissolved and their concentration determined by measuring absorbance at 550 nm. Thus, after overnight seeding of 24-well dishes with 150,000 cells, followed by treatment of the cells with the toxic compounds, 50  $\mu$ l of MTT (Sigma) are added (at a concentration of 5 mg/ml in PBS). The formazan crystal formation reaction is carried out for 5 h in a CO<sub>2</sub>

incubator (37°C, 5% CO<sub>2</sub>, 95% humidity). After addition of 500 µl of solubilization solution (0.1 N HCl in isopropanol-Triton X-100 (10%)), the crystals are dissolved with stirring and their absorbance is measured at 550 to 660 nm. Determinations are done in triplicate with suitable controls (viability, cell death, blanks).

5 A test of apoptosis or programmed cell death was also performed by measuring DNA fragmentation with an anti-histone antibody and ELISA. The Cell Death ELISA Plus from Roche was used.

The results of these three tests (Figures 18 A, B, C) indicate that the following concentrations :

- 10
- ethanol : 0.1 M
  - camptothecin : 1 µg/ml
  - PMA : 50 ng/ml
- were well below the measured IC<sub>50</sub> values.

15 HepG2 cells were thus treated with these three concentrations of these three compounds for 4 h in the case of ethanol and camptothecin and for 18 h in the case of PMA. Messenger RNAs were purified on Dynal-Oligo-(dT) beads starting from total RNAs purified with the Rneasy kit (Qiagen). cDNA was synthesized from these messenger RNAs using Superscript reverse transcriptase (Life Technologies)

20 and random hexamers as primers

These initial strands served as templates for PCR amplification reactions (94°C 1 min, 55°C 1 min, 72°C 1 min, 30 cycles) by means of the following oligonucleotide primers :

25 MACH-α:

5'-TGCCCAAATCAACAAGAGC-3' (SEQ ID NO: 11)

5'-CCCCTGACAAGCCTGAATA-3' (SEQ ID NO: 12)

30 These primers correspond to the regions common to the different described isoforms of MACH-α (1, 2 and 3, respectively amplifying 595, 550 and 343 base pairs). MACH-α (Caspase-8) is a protease involved in programmed cell death (Boldin et al., (1996), Cell, 85: 803-815).



BCL-X :

5' ATGTCTCAGAGCAACCGGGAGCTG 3' (SEQ ID NO: 13)

5' GTGGCTCCATTCACCGCGGGGCTG 3' (SEQ ID NO: 14)

5

These primers correspond to the regions common to the different described isoforms of bcl-X (bcl-XI, bcl-Xs, BCL-X $\beta$ ) (Boise et al., (1993), Cell 74: 597-608; U72398 (Genbank)) and should amplify a single 204 base pair fragment for these three isoforms.

10

FASR:

5'-TGCCAAGAAGGGAAGGAGT-3' (SEQ ID NO: 15)

5'-TGTCATGACTCCAGCAATAG-3' (SEQ ID NO: 16)

15

These primers correspond to the regions common to certain FASR isoforms and should amplify a 478 base pair fragment for wild type form FasR, 452 base pairs for isoform  $\Delta 8$  and 415 for isoform  $\Delta TM$ .

20

The results presented in Figure 19 indicate that :

- Camptothecin induces a decrease in the expression of isoform MACH- $\alpha 1$  and an increase in isoform MACH- $\alpha 3$ .

- Camptothecin induces the appearance of a new bcl-X isoform (upper band in the doublet near 200 base pairs).

25

- Camptothecin induces a decrease in the wild type form of the fas receptor, replaced by expression of a shorter isoform which may correspond to Fas  $\Delta TM$ .

- Ethanol induces the disappearance of bcl-x which is replaced by a shorter isoform.

30

- Ethanol induces an increase in the long wild type form of the fas receptor at the expense of the shorter isoform.

These results demonstrate that treatment with low concentrations of toxic compounds can induce regulation defects in the alternative splicings of certain RNAs, and this in a specific manner. The identification of these regulation defects at

the post-transcriptional level, notably by application of DATAS technology, thus constitutes a tool to predict the toxicity of molecules.

CLAIMS

1. A method for identifying and/or cloning nucleic acid regions representative of qualitative genetic differences occurring between two biological samples,  
5 comprising hybridizing RNAs or double stranded cDNAs derived from a first biological sample with cDNAs derived from a second biological sample.

2. A method according to claim 1, wherein said method comprises :

- (a) hybridizing RNAs derived from the first sample (test condition)  
10 with cDNAs derived from the second sample (reference condition);  
(b) hybridizing RNAs derived from the second sample (reference condition) with cDNAs derived from the first sample (test condition) ; and  
(c) identifying and/or cloning, from the hybrids formed in steps (a) and (b), nucleic acids corresponding to qualitative genetic differences.

15 3. A method according to claim 1 or 2, wherein the hybridizations are performed between RNAs and single stranded cDNAs and wherein it comprises identifying and/or cloning unpaired RNA regions.

20 4. A method according to claim 1 or 2, wherein the hybridizations are performed between RNAs and double stranded cDNAs and wherein it comprises identifying and/or cloning paired DNA regions.

25 5. A method according to claim 1, wherein it comprises hybridizing double stranded cDNAs derived from a first biological sample with single stranded cDNAs derived from a second biological sample.

6. A method according to any one of claims 1 to 5, wherein the biological sample consists of cells, a tissue, an organ or a biopsy sample.

30 7. A method according to any one of claims 1 to 6 for identifying and/or cloning differential alternative forms of splicing occurring between tumoral and non tumoral cells.

8. A method according to any one of claims 1 to 6 for identifying and/or cloning differential alternative forms of splicing occurring between cells treated by a test compound and non treated cells.

5 9. A method according to any one of claims 1 to 6 for identifying and/or cloning differential alternative forms of splicing occurring between cells undergoing apoptosis and non apoptotic cells.

10 10. A method according to any one of claims 1 to 9, wherein hybridization is performed in a liquid phase.

11. A method for identifying and/or cloning differentially spliced nucleic acid regions occurring between two physiological conditions A and B, comprising :

15 (a) generating heteroduplex structures in a liquid phase between the messenger RNAs derived from condition A and the cDNAs derived from condition B on the one hand;

(b) generating heteroduplex structures in a liquid phase between the messenger RNAs derived from condition B and the cDNAs derived from condition A on the other hand ; and

20 (c) identifying and/or cloning unpaired RNA regions within the heteroduplex structures obtained in steps (a) and (b).

12. A method for identifying and/or cloning differentially spliced nucleic acid regions occurring between two physiological conditions A and B, comprising :

25 (a) generating heteroduplex structures between the messenger RNAs derived from condition A and the cDNAs derived from condition B on the one hand, the RNAs or cDNAs being fixed to a support material ;

(b) generating heteroduplex structures between the messenger RNAs derived from condition B and the cDNAs derived from condition A on the other hand, 30 the RNAs or cDNAs being fixed to a support material; and

(c) identifying and/or cloning unpaired RNA regions within the heteroduplex structures obtained in steps (a) and (b).

13. A composition comprising nucleic acids identified and/or cloned

according to the methods of claims 1 to 12.

14. A nucleic acid composition, wherein said composition essentially comprises nucleic acids representative of qualitative genetic differences, notably alternative forms of splicing distinctive of two physiological conditions of a cell or tissue.

15. A composition according to claims 13 or 14, wherein the nucleic acids are cloned into vectors.

10

16. A nucleic acid library comprising nucleic acids specific to qualitative genetic alterations, notably alternative forms of splicing which are distinctive of two physiological conditions of a cell or tissue.

17. A library according to claim 16, wherein said library is a library restricted to alternative forms of splicing characteristic of mature RNAs.

18. A library according to claim 16, wherein said library is a complex library of alternative forms of splicing characteristic of transcripts.

20

19. A library according to claim 16, wherein said library is an autologous library characteristic of alternative forms of splicing occurring between mature and premessenger RNAs of a given physiological condition.

20. A nucleic acid library comprising oligonucleotides or PCR fragments specific to alternative forms of splicing which are distinctive of two physiological conditions.

21. A microorganism library comprising microorganisms transformed by nucleic acids specific to alternative forms of splicing which are distinctive of two physiological conditions of a cell or tissue.

22. A library according to claims 16 to 21, wherein said library is deposited on a support material.

23. A kit comprising a support material upon which is deposited a library according to any one of claims 16 to 21.

5           24. A kit according to claim 23, wherein said kit comprises two libraries according to any one of claims 16 to 21, deposited on a common support or on two individual support materials.

25. A kit according to claims 23 or 24, wherein the support material consists  
10 of a filter, membrane or chip.

26. The use of a composition according to any one of claims 13 to 15 or of a library according to claims 16 to 21 for identifying active molecules.

15           27. The use of a composition according to any one of claims 13 to 15 or of a library according to claims 16 to 21 for identifying proteins or protein domains which are altered in a pathology.

28. The use of a composition according to any one of claims 13 to 15 or of a  
20 library according to claims 16 to 21 for identifying antigenic domains specific to proteins involved in a pathology.

29. A method for identifying and/or producing proteins or protein domains involved in a pathology comprising :

25           (a) hybridizing the messenger RNAs of a pathological sample with the cDNAs derived from a healthy sample, or vice versa, or both in parallel,

             (b) identifying, within the hybrids formed, the regions corresponding to qualitative differences specific to the pathological state as compared to the healthy state,

30           (c) identifying and/or producing the protein or protein domain corresponding to a region identified in step (b).

30. A method for identifying and/or cloning tumor suppressor genes or splicings within tumor suppressor genes, comprising :

(a) hybridizing the messenger RNAs of a tumor sample with the cDNAs of a healthy sample, or vice versa, or both in parallel,

(b) identifying, within the hybrids formed, the regions corresponding to qualitative differences specific to the tumor sample as compared to the healthy sample,

(c) identifying and/or producing a protein or protein domain corresponding to a region identified in step (b).

31. A composition comprising a compound capable of interfering with the products of alternative splicings identified according to the methods of claims 1 to 12.

32. A protein identified using the method of claim 29.

33. The use of a library according to claims 16 to 21 or of a kit according to claims 23 to 25 to evaluate the toxicity of a compound.

34. A method for identifying and/or cloning nucleic acids specific to a toxic state of a given biological sample comprising preparing qualitative differential libraries between the RNAs and the cDNAs from the sample after treatment or no treatment by a toxic test compound, and screening for toxicity markers specific of the characteristics of the sample post-treatment.

35. A method for determining or assessing the toxicity of a test compound to a given biological sample comprising hybridizing :

- differential libraries between the cDNAs and the RNAs of said biological sample in healthy condition and at one or different stages of toxicity as a result of treating said sample with a reference toxic compound, with,

- a nucleic acid preparation of the biological sample treated by said test compound, and

- assessing the toxicity of the test compound by examining the extent of hybridization with the different libraries.

36. A method according to claim 35, wherein the biological sample is a

culture of hepatocytes, renal epithelial cells or endothelial cells, either subjected or not to treatment by a toxic agent, preferably ethanol.

37. A method according to claim 35, wherein the biological sample is a skin  
5 culture either subjected or not to treatment by toxic agents or irritants.

38. The use of a library according to claims 16 to 21 or of a kit according to claims 23 to 25 to evaluate the potency of a compound.

10 39. A method for determining or assessing the therapeutic efficacy of a test compound with respect to a given biological sample comprising hybridizing :

- differential libraries between the cDNAs and the RNAs of said biological sample in healthy and pathological conditions, with,

- a nucleic acid preparation of the biological sample treated by said  
15 test compound, and

- assessing the therapeutic potential of the test compound by examining the extent of hybridization with the different libraries.

20 40. The use of a library according to claims 16 to 21 or of a kit according to claims 23 to 25 to evaluate the responsiveness of a pathological sample to a compound.

41. A method for determining or assessing the responsiveness of a patient to a test compound or treatment comprising hybridizing :

- 25 - differential libraries between the cDNAs and the RNAs of a biological sample responsive to said compound/treatment and of a biological sample unresponsive or poorly responsive to said compound/treatment, with,

- a nucleic acid preparation of a pathological biological sample of the patient, and

- 30 - assessing the responsiveness of the patient by examining the extent of hybridization with the different libraries.

42. A method according to claim 41 for determining or assessing the response of a patient to an anti-tumoral compound or treatment.



43. A method according to claim 42 for determining or assessing the response of a patient to an antitumoral treatment through wild type p53 gene transfer.

5

44. A nucleic acid identified by the method according to claims 1 to 12.

45. The use of a nucleic acid according to claim 44 for detecting genetic defects in a sample.

10

46. The use of a compound according to claim 28 for detecting a genetic defect in a sample.

47. An antibody directed against a protein or protein domain as defined in claim 27 or 28.

15

48. The  $\Delta$ SHC protein with the sequence SEQ ID NO: 9.

49. A nucleic acid probe, oligonucleotide or antibody for identifying the  $\Delta$ SHC protein according to claim 48 or its nucleic acid, and/or a modification of the SHC/ $\Delta$ SHC ratio in a biological sample.

20

50. A screening method, wherein said method is based on blocking the spliced domain in the SHC protein or inhibiting the functions acquired by the spliced protein  $\Delta$ SHC.

25

51. A vector comprising a sequence coding for the  $\Delta$ SHC protein according to claim 48.

30

52. A method according to claims 3, 4 or 5, wherein cloning nucleic acids comprises reverse transcription and/or amplification by means of random or semi-random primers, particularly primers with sequence SEQ ID NO: 3 in which N indicates that each of the four bases may be present randomly at the indicated position, W, X and Y each designate a defined base, and Z designates either a

defined base, or a 3'-OH group.

53. An oligonucleotide comprising, in the 5' ---> 3' orientation :

- a stabilizing region comprising 8 to 24 defined nucleotides,
- a random region comprising 3 to 8 nucleotides, and
- a minimal priming region comprising 2 to 4 defined nucleotides.

54. An oligonucleotide with sequence SEQ ID NO: 3 in which :

- N indicates that each of the four bases may be present randomly at the indicated position;
- W, X and Y each designate a defined base,
- Z designates either a defined base, or a 3'-OH group.

55. A genomic DNA library, wherein said library consists of genomic DNA

fragments whose size is less than or equal to approximately 1 kb.

56. A method for detecting or monitoring the toxicity and/or therapeutic potential of a compound, based on detecting the splicing forms and/or profiles induced by said compound on a biological sample.

57. The use as a source of pharmacogenomic markers of (i) interindividual variability of isoforms generated by alternative splicing (spliceosome analysis) or (ii) splicing alterations induced by treatments.

## ABSTRACT

DIFFERENTIAL SCREENING

The invention concerns a method for identifying and/or cloning nucleic acid regions representing qualitative differences associated with alternative splicing events and/or with insertions, deletions located in RNA transcribed genome regions, between two physiological situations, comprising either hybridization of RNA derived from the test situation with cDNA's derived from the reference situation and/or reciprocally, or double-strand hybridization of cDNA derived from the test situation with cDNA's derived from the reference situation; and identifying and/or cloning nucleic acids representing qualitative differences. The invention also concerns compositions or banks of nucleic acids representing qualitative differences between two physiological situations, obtainable by the above method, and their use as probe, for identifying genes or molecules of interest, or still for example in methods of pharmacogenomics, and profiling of molecules relative to their therapeutic and/or toxic effects. The invention further concerns the use of dysregulation of splicing RNA as markers for predicting molecule toxicity and/or efficacy, and as markers in pharmacogenomics.

09/623828

534 Rec'd POT/PIC 08 SEP 2000

## LISTE DE SEQUENCES

5 <110> EXONHIT THERAPEUTICS SA  
<120> CRIBLAGE DIFFERENTIEL QUALITATIF  
<130>  
10 <140>  
<141>  
<150> 9802997  
<151> 1998-03-11  
15 <160> 16  
<170> PatentIn Ver. 2.1  
20 <210> 1  
<211> 23  
<212> ADN  
<213> Séquence artificielle  
25 <220>  
<223> Description de la séquence artificielle: OLIGO  
<400> 1  
gagaagcggtt atnnnnnnna ggn 23  
30 <210> 2  
<211> 24  
<212> ADN  
<213> Séquence artificielle  
35 <220>  
<223> Description de la séquence artificielle: OLIGO  
<400> 2  
40 gagaagcggtt atnnnnnnnn tccc 24  
<210> 3  
<211> 23  
<212> ADN  
45 <213> Séquence artificielle  
<220>

<223> Description de la séquence artificielle: OLIGO

<400> 3  
 gagaagcgtt atnnnnnnnn nnn 23

5 <210> 4  
 <211> 20  
 <212> ADN  
 <213> Séquence artificielle

10 <220>  
 <223> Description de la séquence artificielle: OLIGO

<400> 4  
 15 gagaagcgtt atnnnnncca 20

<210> 5  
 <211> 66  
 <212> ADN  
 20 <213> Homo sapiens

<400> 5  
 ccacacctgg ccagtatgtg ctcaactggct tgcagagtgg gcagccagcc taagcatttg 60  
 cactgg 66

25 <210> 6  
 <211> 23  
 <212> ADN  
 <213> Séquence artificielle

30 <220>  
 <223> Description de la séquence artificielle: OLIGO

<400> 6  
 35 gggacctgtt tgacatgaag ccc 23

<210> 7  
 <211> 22  
 <212> ADN  
 40 <213> Séquence artificielle

<220>  
 <223> Description de la séquence artificielle: OLIGO

<400> 7  
 45 cagtttccgc tccacaggtt gc 22

<210> 8  
 <211> 96  
 <212> ADN  
 <213> Homo sapiens

5

<400> 8  
 gtacgggaga gcacgaccac acctggccag tatgtgctca ctggcttgca gagtgggcag 60  
 cctaagcatt tgctactggt ggacctgag ggtgtg 96

10

<210> 9  
 <211> 441  
 <212> PRT  
 <213> Homo sapiens

15

<400> 9  
 Met Asn Lys Leu Ser Gly Gly Gly Gly Arg Arg Thr Arg Val Glu Gly  
 1 5 10 15

20

Gly Gln Leu Gly Gly Glu Glu Trp Thr Arg His Gly Ser Phe Val Asn  
 20 25 30

Lys Pro Thr Arg Gly Trp Leu His Pro Asn Asp Lys Val Met Gly Pro  
 35 40 45

25

Gly Val Ser Tyr Leu Val Arg Tyr Met Gly Cys Val Glu Val Leu Gln  
 50 55 60

Ser Met Arg Ala Leu Asp Phe Asn Thr Arg Thr Gln Val Thr Arg Glu  
 65 70 75 80

30

Ala Ile Ser Leu Val Cys Glu Ala Val Pro Gly Ala Lys Gly Ala Thr  
 85 90 95

35

Arg Arg Arg Lys Pro Cys Ser Arg Pro Leu Ser Ser Ile Leu Gly Arg  
 100 105 110

Ser Asn Leu Lys Phe Ala Gly Met Pro Ile Thr Leu Thr Val Ser Thr  
 115 120 125

40

Ser Ser Leu Asn Leu Met Ala Ala Asp Cys Lys Gln Ile Ile Ala Asn  
 130 135 140

His His Met Gln Ser Ile Ser Phe Ala Ser Gly Gly Asp Pro Asp Thr  
 145 150 155 160

45

Ala Glu Tyr Val Ala Tyr Val Ala Lys Asp Pro Val Asn Gln Arg Ala  
 165 170 175

50

Cys His Ile Leu Glu Cys Pro Glu Gly Leu Ala Gln Asp Val Ile Ser  
 180 185 190

Thr Ile Gly Gln Ala Phe Glu Leu Arg Phe Lys Gln Tyr Leu Arg Asn  
 195 200 205

55

Pro Pro Lys Leu Val Thr Pro His Asp Arg Met Ala Gly Phe Asp Gly  
 210 215 220


Ser Ala Trp Asp Glu Glu Glu Glu Glu Pro Pro Asp His Gln Tyr Tyr

	<400> 10	
	atgaacaagc tgaagtggag cgcgggcgcg aggactcggg tggaaagggg ccagcttgagg	60
	ggcagaggat ggaccgcgcca cgggagcgtt gtcaataaag ccacgcgggg ctggctgcac	120
50	cccaacgaca aagcatctgg acccggggtt tctacttgg ttcggtacat ggggtgtgtg	180
	gaggctctcc agtcaatgcg tgccctggac ttcaacaccc ggactcaggt caccaggggag	240
	ggcatcagtc tggttgtgtg gctgtgtcgg ggtctgaagg ggcgacaag gaggagaaag	300
	ccctgtagcc gcccgctcgc cctctatcct gggaggagta acctgaatt tgcgtgaatt	360
	ccaatcactc taccggtctc caccagcagc ctcaaacctca tggccgcaga ctgcaaacag	420
55	atcatcgcca accacacat gcaattctat tcatttgcac ccggcgggga tccggacaca	480
	gcgagtagta tgcgcattgt tgccaaagac cctgtgaatc agagagcctc ccacattctg	540
	gagtgatccc aaggccttgc ccaggaattc atcagacca ttggccagcg cttcgaattg	600


	cgcttcaaac aatacctcag gaacccaccc aaactggtea cccctcatga caggatggct	660
	ggctttgatg gctcagcatg ggatgaggag gaggaagagc cacctgacca tcagtactat	720
	aatgacttcc cggggaagga accccccttg ggggggggtg tagacatgag gcttcgggaa	780
	ggagccgctc caggggctgc tggacccact gcacccaatg cccagacccc cagccacttg	840
5	ggagctacat tgcctgtagg acagcctgtt ggggggagatc cagaagtcog caaacagatg	900
	ccacctccac caccctgtcc aggcagagag ctttttgatg atccctccta tgtcaacgtc	960
	cagaacctag acaaggcccg gcaagcagtg ggtggtgctg ggccccccaa tctgtctatc	1020
	aatggcagtg caccocggga cctgtttgac atgaagccct tgaagatgc tcttcgggtg	1080
	cctccacctc cccagtcggt gtccatggct gagcagctcc gaggggagcc ctggttccat	1140
10	gggaagctga gccggcgga ggctgaggca ctgctgcagc tcaatgggga cttcttggtt	1200
	oggactaagg atcaccgctt tgaaagtgtc agtcacctta tcagctacca catggacaat	1260
	cacttgcccc tcactctctg gggcagcgaa ctgtgtctac agcaacctgt ggagcggaaa	1320
	ctgtga	1326
15	<210> 11	
	<211> 19	
	<212> ADN	
	<213> Séquence artificielle	
	b	
20	<220>	
	<223> Description de la séquence artificielle: OLIGO	
	<400> 11	
	tgcccaaadc aacaagagc	19
25	<210> 12	
	<211> 19	
	<212> ADN	
	<213> Séquence artificielle	
30	<220>	
	<223> Description de la séquence artificielle: OLIGO	
	<400> 12	
35	ccctgacaa gcttgaata	19
	<210> 13	
	<211> 24	
	<212> ADN	
40	<213> Séquence artificielle	
	<220>	
	<223> Description de la séquence artificielle: OLIGO	
45	<400> 13	
	atgtctcaga gcaaccggga gctg	24




<210> 14  
 <211> 24  
 <212> ADN  
 <213> Séquence artificielle  
 5  
 <220>  
 <223> Description de la séquence artificielle: OLIGO  
 10 <400> 14  
 gtggctccat tcaccgctgg gctg 24  
 <210> 15  
 <211> 19  
 15 <212> ADN  
 <213> Séquence artificielle  
 <220>  
 <223> Description de la séquence artificielle: OLIGO  
 20 <400> 15  
 tgccaagaag ggaaggagt 19  
 <210> 16  
 25 <211> 20  
 <212> ADN  
 <213> Séquence artificielle  
 <220>  
 30 <223> Description de la séquence artificielle: OLIGO  
 <400> 16  
 tgtcatgact ccagcaatag 20


**FIGURE 1A**

2/26


**FIGURE 1B**

3/26

**FIGURE 1C**




5/26

**FIGURE 2**

6/26

path. RNA/normal cDNA hybrids



non spliced sequences after RNase H digestion

=====

desired sequence which is 5'- and 3'-  
labelled by two oligonucleotides

III-=====GGG



PCR-amplified fragment


III-=====GGG



cloning and sequencing


**FIGURE 3**

7/26



**FIGURE 4**



8/26

**FIGURE 5**

9/26





Conditions A and B  
of cDNA



mRNA

1st strands of cDNA  
in conditions A and B


2nd strand of cDNA in A




Hybridization of the 2 strands of A  
with the 1st strand of B



Digestion with Sau3AI



Separation of loops engaged into duplex




Addition of linkers to the sites Sau3AI




PCR Amplification and cloning

**FIGURE 6A**

10/26


**FIGURE 6B**

11/26

**FIGURE 7**

12/26

Figure 8



13/26




Figure 9

14/26

1 2 3 4 5 6 7 8 9 10 11 12 13





Figure 10

15/26

A)



B)




Figure 11



16/26






Figure 12


17/26




Construction of qualitative differential libraries corresponding to different dots of toxicity abacus-like charts




Hybridization with probes derived from the model treated by different products



**FIGURE 13**

**FIGURE 14**

**FIGURE 15**

induced cells

N1 M1 L1 K1 J1 H1 H1 G1 F1 E1



N1 M1 L1 K1 J1 H1 H1 G1 F1 E1



non-induced cells

B

A




Figure 16

**Peptidic Sequence of ASHC (SEQ ID NO: 9)**

1

MNKLSGGGGR RTRVEGGQLG GEEWTRHGSF VNKPTRGWLH PNDKVMGPGV  
 SYLVRYMGCV EVLQSMRALD FNTRTQVTRE AISLVCEAVP GAKGATRRRK  
 PCSRPLSSIL GRSNLKFAGM PITLTVSTSS LNLMAADCKQ IIANHHMQSI  
 SFASGGDPDT AEYVAYVAKD PVNQRACHIL ECPEGLAQDV ISTIGQAFEL  
 RFKQYLRNPP KLVTPHDRMA GFDGSAWDEE EEEPPDHQYY NDFPGKEPPL  
 GGVDMLRLRE GAAPGAARPT APNAQTPSHL GATLPVGQPV GGDPEVRKQM  
 PPPPPCPGRE LFDDPSYVNV QNLDKARQAV GGAGPPNPAI NGSAPRDLFD  
 MKPFEDALRV PPPPQSVSMA EQLRGEPPWFH GKLSRREAEE LLQLNGDFLV  
 RTKDHRESFV SHLISYHMDN HLPPIISAGSE LCLQQPVERKL

441

**Nucleic Sequence of ASHC (SEQ ID NO: 10)**

atgaacaagc	tgagtggagg	cgcgccggcg	aggactcggg	tggaaggggg	50
ccagcttggg	ggcgaggagt	ggacccgcca	cgggagcttt	gtcaataagc	100
ccacgcgggg	ctggctgcat	cccaacgaca	aagtcatggg	acccgggggt	150
tcctacttgg	ttcggtacat	gggttggtg	gaggtcctcc	agtcaatgcg	200
tgccctggac	ttcaacaccc	ggactcaggt	caccaggagg	gccatcagtc	250
tggtgtgtga	ggctgtgccg	ggtgctaagg	ggcgacaag	gaggagaaa	300
ccctgtagcc	gcccgcctcag	ctctatcctg	gggaggagta	acctgaaatt	350
tgctggaatg	ccaatcactc	tcaccgtctc	caccagcagc	ctcaacctca	400
tgcccgagca	ctgcaaacag	atcatcgcca	accaccacat	gcaatctatc	450
tcatttgc	ccggcgggga	tccggacaca	gccgagtagt	tcgcctatgt	500
tgccaagac	cctgtgaatc	agagagcctg	ccacattctg	gagtgctccg	550
aagggttgc	ccaggatgtc	atcagcacca	ttggccaggc	cttcgagttg	600
cgcttcaaac	aatacctcag	gaacccaccc	aaactgggtc	cccctcatga	650
caggatggct	ggctttgatg	gctcagcatg	ggatgaggag	gaggaagagc	700
cacctgacca	tcagtactat	aatgacttcc	cggggaagga	accccccttg	750
gggggggtgg	tagacatgag	gcttcgggaa	ggagccgctc	caggggctgc	800
tcgaccact	gcacccaatg	cccagacccc	cagccacttg	ggagctacat	850
tgctgtagg	acagcctgtt	gggggagatc	cagaagtcgg	caaacagatg	900

**FIGURE 17A**

22/26


ccacctccac caccctgtcc aggcagagag ctttttgatg atccctccta 950  
tgtcaacgtc cagaacctag acaaggcccg gcaagcagtg ggtggtgctg 1000  
ggccccccaa tcctgtctatc aatggcagtg caccocggga cctgtttgac 1050  
atgaagccct tcgaagatgc tcttcgggtg cctccacctc ccagtcggt 1100  
gtccatggct gagcagctcc gaggggagcc ctggttccat gggaagctga 1150  
gccggcggga ggctgaggca ctgctgcagc tcaatgggga cttcttggtt 1200  
cggactaagg atcaccgctt tgaaagtgtc agtcacctta tcagctacca 1250  
catggacaat cacttgccca tcctctctgc gggcagcgaa ctgtgtctac 1300  
agcaacctgt ggagcggaaa ctgtga 1326

**FIGURE 17B**


23/26

# Trypan Blue


## HepG2 / Ethanol



## MTT Test

**FIGURE 18A**

## ELISA Test - Fragmentation of DNA






24/26

## HepG2 / Camptothecin

Trypan Blue



MTT Test





FIGURE 18B


ELISA Test - Fragmentation of DNA




25/26

## HepG2 / PMA

Trypan Blue





Test MTT



ELISA Test - Fragmentation of DNA

FIGURE 18C





PATENT  
ATTORNEY DOCKET NO: 50146/004002

### COMBINED DECLARATION AND POWER OF ATTORNEY

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled QUALITATIVE DIFFERENTIAL SCREENING, the specification of which

☐ is attached hereto.

☒ was filed on September 8, 2000 as Application Serial No. 09/623,828  
and was amended on \_\_\_\_\_.

☐ was described and claimed in PCT International Application No. \_\_\_\_\_  
filed on \_\_\_\_\_ and as amended under PCT Article 19 on \_\_\_\_\_.

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose all information I know to be material to patentability in accordance with Title 37, Code of Federal Regulations, §1.56(a).

**FOREIGN PRIORITY RIGHTS:** I hereby claim foreign priority benefits under Title 35, United States Code, §119 of any foreign application(s) for patent or inventor's certificate or of any PCT international application(s) designating at least one country other than the United States of America listed below and have also identified below any foreign application for patent or inventor's certificate or any PCT international application(s) designating at least one country other than the United States of America filed by me on the same subject matter having a filing date before that of the application(s) of which priority is claimed:

Country	Serial Number	Filing Date	Priority Claimed?
France	98 02997	March 11, 1998	Yes
PCT	PCT/FR 99/00547	March 11, 1999	Yes

**PROVISIONAL PRIORITY RIGHTS:** I hereby claim priority benefits under Title 35, United States Code, §119(e) and §120 of any United States provisional patent application(s) listed below filed by an inventor or inventors on the same subject matter as the present application and having a filing date before that of the application(s) of which priority is claimed:

Serial Number	Filing Date	Status

**NON-PROVISIONAL PRIORITY RIGHTS:** I hereby claim the benefit under Title 35, United States Code,

# COMBINED DECLARATION AND POWER OF ATTORNEY

§120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code, §112, I acknowledge the duty to disclose all information I know to be material to patentability as defined in Title 37, Code of Federal Regulations, §1.56(a) which became available between the filing date of the prior application and the national or PCT international filing date of this application:


Serial Number	Filing Date	Status
09/046,920	March 24, 1998	Pending

I hereby appoint the following attorneys and/or agents to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith: Paul T. Clark, Reg. No. 30,162, Karen L. Elbing, Ph.D. Reg. No. 35,238, Kristina Bieker-Brady, Ph.D. Reg. No. 39,109, Susan M. Michaud, Ph.D. Reg. No. 42,885, Mary Rose Scozzafava, Ph.D., Reg. No. 36,268, James D. DeCamp, Ph.D., Reg. No. 43,580, Sean J. Edman, Reg. No. 42,506, Timothy J. Douros, Reg. No. 41,716.

Address all telephone calls to: Kristina Bieker-Brady, Ph.D. at 617/428-0200.


Address all correspondence to: Kristina Bieker-Brady, Ph.D. at Clark & Elbing LLP, 176 Federal Street, Boston, MA 02110.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patents issued thereon.


Full Name (First, Middle, Last)	Residence Address (City, State, Country)	Post Office Address (Street, City, State, Country)	Citizenship
<u>Fabien Schweighoffer</u>	<u>Vincennes, France</u> <sup>3RX</sup>	<u>38 avenue Paul Déroulède</u> <u>94300 Vincennes, France</u>	French
Signature: 			Date: <u>4/10/00</u>

# COMBINED DECLARATION AND POWER OF ATTORNEY

2-00

Full Name (First, Middle, Last)	Residence Address (City, State, Country)	Post Office Address (Street, City, State, Country)	Citizenship
<u>Laurent Bracco</u>	<u>Paris, France</u> <i>JKX</i>	30 rue Deparcieux 75014 Paris, France	French
Signature: 			Oct. 26, 2000 Date:

3-00

Full Name (First, Middle, Last)	Residence Address (City, State, Country)	Post Office Address (Street, City, State, Country)	Citizenship
<u>Bruno Tocque</u>	<u>Courbevoie, France</u> <i>JKX</i>	58 boulevard Saint-Denis 92400 Courbevoie, France	French
Signature: 			Oct. 26, 2000 Date: